yevkhtm form ktable content united states securities exchange commission washington annual report pursuant section security exchange act fiscal year end december transition report pursuant section security exchange act transition period commission file number scheringplough corporation exact registrant specify charter new jersey state jurisdiction irs employer incorporation organization identification gallop hill road kenilworth address principal executive office zip code registrant telephone number include area code security register pursuant section act title class exchange register common share par value new york stock exchange mandatory convertible preferred stock new york stock exchange security register pursuant section act indicate check mark registrant wellknown seasoned issuer define rule security act yes indicate check mark registrant require file report pursuant section section act yes indicate check mark registrant file report require file section security exchange act precede month short period registrant require file report subject filing requirement past day yes indicate check mark disclosure delinquent filer pursuant item regulation chapter contain contain good registrant knowledge definitive proxy information statement incorporate reference iii amendment indicate check mark registrant large accelerated filer accelerate filer nonaccelerate filer small reporting company definition large accelerate filer accelerate fil small reporting company rule exchange act check large accelerated filer accelerate filer nonaccelerate filer small reporting company check small reporting company indicate check mark registrant shell company define rule act yes state aggregate market value vote nonvoting common equity hold nonaffiliate compute reference price common equity sell average bid ask price common equity june business day registrant recently complete second fiscal quarter common share outstanding january document incorporate refe rence incorporate scheringplough corporation proxy statement iii annual meeting shareholder file day close registrant fiscal year proxy statementtable content age item business item risk factor item unresolved staff comment item property item legal proceeding item submission matter vote security holder executive officer registrant item market registrant common equity relate stockholder matter issuer purchase equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure management report internal control financial reporting item information iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accounting fee service item exhibit financial statement schedule signature exd stock incentive plan exexv form employment agreement exk saving advantage plan exl supplemental executive retirement plan exm retirement benefit equalization plan computation ratio earning fix charge subsidiary consent independent register public accounting firm independent auditor consent power attorney certification certification certifcation certification table content item business overview business scheringplough refer scheringplough corporation subsidiary indicate context schering corporation predecessor company incorporate new york new jersey trademark indicate capital letter property license promote distribute scheringplough corporation subsidiary relate company scheringplough innovationdriven sciencecentere global health care company biopharmaceutical research collaboration partner scheringplough create therapy help save improve life world scheringplough apply research development platform prescription pharmaceutical animal health consumer health care product scheringploughs vision earn trust day doctor patient customer shareholder employee stakeholder scheringplough base kenilworth web site wwwscheringploughcom april board director recruit fred hassan join scheringplough new chairman board chief executive officer support board soon arrive hassan instal new senior executive management team initiate strategic plan goal stabilize repair turn scheringplough order build longterm shareholder value strategic plan action agenda eightyear fivephase plan year hassan new management team arrive scheringplough substantial progress fourth phase action agenda build base scheringplough grow broaden base market product expand latestage research development project pipeline substantial progress integration organon bioscience obs purchase akzo nobel late acquisition transformative give scheringplough key new pipeline project include asenapine schizophrenia bipolar disease sugammadex reverse deep anesthesia key product new therapeutic area women health central nervous system position leader animal health combine scheringplough animal health intervet leadership position animal vaccine intervet earlystage innovation capability human vaccine nobilon additional stateoftheart biologic capabilitie substantial expansion company geographic footprint significant talent include key research development function strength gain progress action agenda key scheringplough period challenge pharmaceutical industry particularly general economy addition scheringplough face particular challenge cholesterol product zetia vytorin particularly discuss item legal proceeding spite challenge scheringplough deliver strong operational performance stock price suffer significant pressure productivity transformation program announce april facilitate scheringplough achievement goal program include ongoing integration ob create lean strong company support scheringplough goal build longterm high performance despite current challenging pharmaceutical industry environment particular challenge face schere plough program target saving billion annualize basis design reduce avoid cost increase productivity total target saving approximately billion table content anticipate accomplished end balance achieve target saving envision program include result previously announce obs integration synergy program scheringplough anticipate invest new highpriority clinical trial pursuit strategic opportunity include product launch anticipate natural cost growth environment continue challenge company geographie uncertainty stock market current credit condition financial market pressure pharmaceutical market include uncertainty regulatory process approve new drug new indication review labeling indication market product assess information risk associate drug human health involve balance quest new innovation particularly address urgent unmet medical need desire minimize risk currently balance strongly skewed risk minimization result long delay approve product great cost clinical trial postmarkete trial increase scrutiny patient prescriber regulatory agency media scheringplough pharmaceutical product subject increasingly competitive pricing certain intermediary include manage care group institution government agency seek price discount international market scheringplough operate environment governmentmandate costcontainment program price sale marketing program arrangement relate business practice scheringplough participant health care industry continue scrutiny federal state regulatory investigative prosecutorial administrative entity segment information scheringplough reportable segment prescription pharmaceutical animal health consumer health care segment sale profitloss datum follow consistent scheringplough current management reporting structure prescription pharmaceutical prescription pharmaceutical segment discover develop manufacture market human pharmaceutical product prescription pharmaceutical segment scheringplough broad range research project market product therapeutic area cardiovascular central nervous system immunology infectious disease oncology respiratory women health prescription pharmaceutical segment include nobilon human vaccine development unit diosynth thirdparty manufacturing unit market product include follow cardiovascular disease vytorin cholesterollowere tablet combine dual action zetia merck incs merck statin zocor simvastatin zetia novel cholesterolabsorption inhibitor discover scheringplough scientist use monotherapy combination statin fenofibrate low cholesterol integrilin injection platelet receptor iibiiia inhibitor treatment patient acute coronary syndrome undergo percutaneous coronary intervention prevention early myocardial infarction patient acute coronary syndrome country orgaran nonheparin antithrombotic central nervous system remeron antidepressant esmeronzemuron muscle relaxant surgical procedure subutex sublingual tablet formulation buprenorphine suboxone sublingual tablet combination buprenorphine naloxone market scheringplough certain country outside treatment opiate addiction norcuron muscle relaxant bridion sugammadex anesthesia reversal agent launch european union countrie review immunology infectious disease remicade antitnf antibody market scheringplough outside united states japan certain asian market treatment inflammatory disease rheumatoid arthritis early rheumatoid arthritis psoriatic arthritis crohns disease ankylose spondylitis plaque psoriasis ulcerative colitis pegintron powder injection pegylate interferon product chronic hepatitis rebetol capsule use combination pegintron intron table content treat hepatitis avelox scheringplough market broadspectrum fluoroquinolone antibiotic certain respiratory skin infection noxafil oral suspension prophylaxis prevention invasive fungal infection highrisk patient treatment oropharyngeal candidiasis approve treatment invasive fungal infection market outside oncology temodartemodal certain type brain tumor include newly diagnose glioblastoma multiforme caelyx longcirculating pegylate liposomal formulation cancer drug doxorubicin market scheringplough outside treatment certain ovarian cancer kaposis sarcoma metastatic breast cancer intron injection market chronic hepatitis numerous anticancer indication worldwide include adjuvant therapy malignant melanoma respiratory nasonex oncedaily nasalinhale steroid nasal allergy symptom include congestion treatment nasal polyp patient year age old clarinexaeriusclaritin nonsedate antihistamine treatment allergic rhinitis foradil aerolizer longacting betaagonist market scheringplough maintenance treatment asthma chronic obstructive pulmonary disease acute prevention exercise induce bronchospasm asmanex twisthaler oral drypowder corticosteroid inhaler firstline maintenance treatment asthma proventil hfa albuterol inhalation aerosol relief bronchospasm patient year old women health follistimpuregon fertility treatment nuvare vaginal contraceptive ring livial menopausal therapy marvelondesogen lowdose combine oral contraceptive mercilon lowdose combine oral contraceptive cerazette progestin oral contraceptive implanon singlerod subdermal contraceptive implant animal health animal health segment discover develop manufacture market animal health product include vaccine principal market product segment include livestock product nuflor antibiotic range use cattle swine bovilisvista vaccine line infectious disease cattle banamine bovine swine antiinflammatory trimerit datum management tool cattle estrumate treatment fertility disorder cattle regumatematrix fertility management swine horse resflor combination broadspectrum antibiotic nonsteroidal antiinflammatory drug bovine respiratory disease zilmax revalor improve production efficiency beef cattle mpac swine pneumonia vaccine stimulate fertility swine porcilis vaccine line infectious disease swine poultry product nobilisinnovax vaccine line poultry paracox coccivac coccidiosis vaccine poultry companion animal product nobivaccontinuum vaccine line flexible dog cat vaccination otomaxmometamaxposatex ear ointments acute chronic otitis caninsulinvetsulin diabete mellitus treatment dog cat panacursafeguard broadspectrum anthelmintic dewormer use animal scaliborexspot protect bite flea tick mosquitoe sandfly homeagain proactive pet recovery network aquaculture product slice parasiticide sea lice salmon aquavacnorvax vaccine bacterial viral disease fish compact vaccine salmon aquaflor antibiotic farmraised fish table content consumer health care consumer health care segment develop manufacture market overthecounter otc foot care sun care product principal product segment include overthecounter product claritin nonsedate antihistamine miralax treatment occasional constipation coricidin hbp decongestantfree coldflu medicine people high blood pressure afrin nasal decongestant spray correctol laxative tablet foot care scholl foot care product lotrimin topical antifungal product tinactin topical antifungal product foot sneaker odorwetness product sun care coppertone sun care lotion spray dry oil lipprotection product sunless tanning product solarcaine sunburn relief product net sale segment ende decem dollar million prescription pharmaceutical animal health consumer health care consolidate net sale profit loss segment yea end decem dollar million prescription pharmaceutical animal health consumer health care corporate include net interest expenseincome million million million respectively consolidated profitloss tax cumulative effect change accounting principle prescription pharmaceutical segment profit include charge arise purchase accounting item million animal health segment profit include charge arise purchase accounting item million prescription pharmaceutical segment loss include billion purchase accounting item include acquire inprocess research development billion animal health segment loss include million purchase accounting item include acquire inprocess research development million scheringplough net sale include sale vytorin zetia manage joint venture merck scheringplough account joint venture equity method accounting note equity income item financial statement supplementary datum additional information equity income merckscheringplough joint venture include prescription pharmaceutical segment corporate include interest income expense foreign exchange gain loss currency option gain headquarters expense special acquisitionrelate charge miscellaneous item table content accounting policy segment report describe note summary significant accounting policy item financial statement supplementary datum corporate include special acquisitionrelate charge million comprise million integration relate cost million employee termination cost relate productivity transformation program include ongoing integration obs estimate charge relate reportable segment follow prescription pharmaceutical million animal health million consumer health million corporate million corporate include special acquisitionrelate charge million comprise million integration relate cost obs acquisition million employee termination cost integration activity estimate charge relate reportable segment follow prescription pharmaceutical million animal health million corporate million corporate include special charge million primarily relate change scheringploughs manufacturing operation puerto rico announce june relate prescription pharmaceutical segment include cost sale charge approximately million manufacturing streamlining action primarily relate prescription pharmaceutical segment note special acquisitionrelate charge manufacture streamline item financial statement supplementary datum additional information information merckscheringplough joint venture scheringplough merck enter separate set agreement jointly develop manage certain product include cholesterollowere drug allergyasthma drug december cholesterol agreement expand include country world japan general company agree collaborative activity agreement operate virtual joint venture rely maximum degree possible respective infrastructure company agreement generally provide equal sharing development cost copromotion approve product company second quarter joint venture relate allergyasthma drug terminate accordance agreement pursuant cholesterol agreement scheringplough grant joint venture limit exclusive license scheringplough proprietary ezetimibe molecule technology cholesterol agreement provide scheringplough merck develop commercialize ezetimibe cholesterol management field joint venture oncedaily monotherapy market zetia asia ezetrol europe coadministration approve statin drug iii fixedcombination tablet ezetimibe simvastatin zocor merck cholesterolmodifye medicine combination medication ezetimibesimvastatin market vytorin inegy international country zetiaezetrol ezetimibe vytorininegy combination ezetimibesimvastatin approve use launch international market scheringplough utilize equity method accounting recording share activity merckscheringplough joint venture note equity income item financial statement supplementary datum additional information profit cost share accounting provide agreement table content allergyasthma agreement provide joint development marketing company oncedaily fixedcombination tablet contain loratadinemontelukast april merckscheringplough joint venture receive notapprovable letter food drug administration fda propose fix combination loratadinemontelukast second quarter respiratory joint venture terminate accordance agreement action impact cholesterol joint venture result termination respiratory joint venture scheringplough receive payment total million scheringplough recognize equity income scheringplough merck develop singletablet combination ezetimibe atorvastatin treatment elevate cholesterol level information centocor license remicade prescribe treatment inflammatory disease rheumatoid arthritis early rheumatoid arthritis psoriatic arthritis crohns disease ankylose spondylitis plaque psoriasis ulcerative colitis remicade scheringplough second large market pharmaceutical product line cholesterol franchise remicade license manufactured centocor inc johnson johnson company scheringplough exercise option contract centocor license right develop commercialize golimumab fully human monoclonal antibody file approval europe scheringplough exclusive marketing right product outside japan certain asian market december scheringplough centocor revise distribution agreement development commercialization distribution remicade golimumab extend scheringplough exclusive right market remicade match duration scheringplough exclusive marketing right golimumab effective regulatory approval golimumab scheringploughs marketing right product extend year commercial sale golimumab centocor receive progressively increase share profit scheringplough distribution product scheringplough marketing territory share profit remain fixed remainder term change duration remicade marketing right profit share arrangement product condition approval golimumab grant prior september scheringplough independently develop market golimumab crohns disease indication territory option centocor participate addition scheringplough centocor agree utilize autoinjector device commercialization golimumab agree share development cost global operation majority scheringplough operation outside acquisition obs late scheringploughs global operation prescription pharmaceutical animal health increase nonus activity carry primarily whollyowne subsidiary market potential adequate circumstance permit addition scheringplough represent market licensee distribution arrangement currently scheringplough business operation country additional information global operation item management discussion analysis financial condition result operation segment information describe net sale geographic area dollar millions united states europe canada latin america asia pacific consolidated net sale table content scheringplough subsidiary country outside united states net sale present geographic area scheringplough customer locate follow country account percent consolidated net sale past year consolidated net consolidated net consolidated net sale net sale sale net sale sale net sale dollar million total international net sale france japan germany canada net sale customer sale single customer account percent scheringploughs consolidate net sale past year follow consolidated net consolidated net consolidated net sale net sale sale net sale sale net sale dollar million mckesson corporation cardinal health supplemental sale information sale product comprise percent scheringplough international sale year end december follow ercentage applicable sale dollar million nasonex international remicade scheringplough net sale include sale vytorin zetia manage joint venture merck scheringplough account joint venture equity method accounting longlive asset geographic location dollar millions united states netherlands ireland singapore total table content longlive asset show geographic location primarily propertie significant increase longlive asset obs acquisition scheringplough disaggregate asset segment basis internal management report information present research development scheringplough research activity primarily aim discover develop new prescription product enhancement exist human prescription product medical commercial significance scheringplough research development platform support animal health consumer health care product research development project application product segment significant work current management team increase productivity efficiency research activity action agenda produce tangible result scheringplough increase number new molecular entity phase iii yearend preregistration total latestage development companysponsore research development expenditure billion billion billion respectively percentage consolidated net sale research development expenditure represent approximately percent percent percent respectively scheringplough research activity concentrate therapeutic area focus cardiovascular central nervous system immunology infectious disease oncology respiratory women health scheringplough research activity include significant biotechnology immunology vaccine development effort reflect portfolio balance small molecule biologic product research activity include expenditure internal research effort research collaboration partner number pharmaceutical compound vary stage development predict compound available commercial sale scheringplough product pipeline list significant product development available scheringploughs web site wwwscheringploughcom nature development approval process fact human health involve science human health constantly evolve status compound development subject change scheringplough assume duty update information scheringplough research development project grant fasttrack designation fda include novel thrombin receptor antagonist acute coronary syndrome secondary prevention subsequent cardiovascular event boceprevir protease inhibitor compound hepatitis vicriviroc ccr receptor antagonist treatment hiv preladenant adenosine receptor antagonist treatment parkinson disease sch generation protease inhibitor compound hepatitis formulation posaconazole currently approve country treatment prophylaxis certain fungal infection product phase iii clinical testing phase thrombin receptor antagonist boceprevir vicriviroc significant expenditure require progress development large number patient necessary phase iii trial scheringplough continue expect research development expense increase year primary reason scheringplough pipeline large new management team focus make research development productive additional pipeline project add obs acquisition reason include need large clinical trial frequent clinical trial long clinical trial current global regulatory environment research development activity typically continue product market reason develop new indication product reason understand benefit risk know people use product long period time require need incremental safety efficacy testing table content regulatory authority world place increase emphasis postapproval commitment form new study registry etc initial approval patent trademark intellectual property right overview intellectual property protection critical scheringplough ability successfully commercialize product innovation schere plough own apply license right large number patent country relate compound formulation use manufacturing process assurance patent scheringplough seeking grant patent scheringplough grant find valid challenge patent relate particular formulation use process preclude manufacturer employ alternative process market alternative formulation use successfully compete scheringplough patent product outside standard intellectual property protection pharmaceutical vary widely country reasonably strong patent law country currently provide little effective protection invention intellectual property right traderelate aspect intellectual property agreement trip administer world trade organization wto country agree provide nondiscriminatory protection pharmaceutical invention assure adequate effective right available patent owner possible change agreement future diminish delay implementation develop country soon assess scheringplough impact commercially change product patent expire patent holder lose effective market exclusivity product result rapid sharp material decline sale patent product particularly case innovator company obtain additional commercial benefit manufacture trade secret laterexpire patent process use formulation trademark use exclusivity available pharmaceutical regulatory law scheringplough intellectual property portfolio patent protection certain scheringplough compound formulation process use important scheringploughs business financial result scheringplough product addition patent compound scheringplough hold patent manufacturing process formulation use extend exclusivity expiration compound patent scheringplough subsidiary license right number patent patent application abroad patent patent application relate scheringplough significant product include limitation vytorin zetia remicade nasonex follistimpuregon nuvare temodar pegintron clarinex material importance scheringplough worldwide scheringplough sell major product trademark material aggregate business financial result trademark protection vary world protection continue country long mark country long register registration normally fix renewable term patent challenge hatchwaxman act drug price competition patent term restoration act commonly know hatchwaxman complex set change patent new drug approval law hatchwaxman drug approve provide fda complete safety efficacy study know complete new drug application nda hatchwaxman authorize fda approve generic version innovative medicine information file abbreviate new drug table content application anda anda generic manufacturer demonstrate bioequivalence generic version nda approve drug safety efficacy hatchwaxman provide limited patent term restoration partially patent term lose time ndaapprove drug regulatory review ndaapprove drug receive limited period datum exclusivity prevent approval anda application specific time period approval ndaapprove drug absent successful patent challenge fda approve anda innovators patent list innovator fda orange book expire generic manufacturer file anda seek approval expiration applicable datum exclusivity allege patent list innovators nda invalid infringe allegation commonly know paragraph certification innovator file suit generic manufacturer protect patent ndaliste patent successfully challenge fil paragraph certification entitle day period market exclusivity generic manufacturer generic manufacturer paragraph certification extensively challenge patent wide array innovative pharmaceutical anticipate trend continue recent year certain generic company elect launch generic product risk patent litigation ongoing decision reach court scheringplough include list hatchwaxman act challenge patent legal proceeding section marketing activity competition scheringplough marketing organization train professional sale representative introduce make know prescription drug health care provider physician pharmacist hospital pharmacy benefit manager manage care organization employer buy group government agency scheringplough introduce make know prescription product journal advertise direct mail advertising distribution sample physician scheringplough communicate directly consumer television radio internet print advertising medium scheringplough believe advertising benefit public health increase awareness disease educate patient treatment option motivate patient engage dialogue health concern physician scheringplough sell prescription drug wholesale specialty distributor hospital certain manage care organization retail specialty pharmacist government agency scheringplough train professional sale representative promote animal health product veterinarian distributor animal producer scheringplough sell overthecounter otc foot care sun care product wholesale retail drug food chain mass merchandiser outlet scheringplough promote directly consumer television radio internet print advertising medium appropriate scheringplough seek regulatory approval switch prescription product overthecounter status way otc marketplace mean maximize return investment discovery development pharmaceutical industry highly competitive include large company significantly large scheringplough substantial resource research product development advertising promotion field sell support competitive pressure intensify pressure environment intensify numerous domestic international competitor industry principal competitive technique scheringplough product include research development new innovative improve product vary dosage form strength switch prescription product nonprescription status scheringploughs product subject increasingly competitive pricing manage care group institution federal state government entity agency buy group seek price discount rebate governmental thirdparty payer practice pharmacist table content pressure dispense generic product significantly reduce sale certain product compete product therapeutic category long protect patent exclusivity available pharmaceutical regulatory law outside similar competitive pressure additionally europe international market government regulate pharmaceutical price access control cost government sponsor healthcare system possibility medicare act amend allow federal government negotiate price directly manufacturer additionally state consider price control access constraint medicaid program government regulation scheringplough major business segment subject significant regulation multiple jurisdiction section describe general regulatory framework additional information cost regulatory compliance specific impact scheringplough business financial condition describe head regulatory competitive environment scheringplough operate management discussion analysis later additional information regulatory matter find note legal environmental regulatory matter item financial statement supplementary datum prescription pharmaceutical segment regulation apply phase business include regulatory requirement conduct standard clinical trial example require use good clinical practice gcp apply research development stage regulatory requirement conduct standard postapproval clinical trial require regulatory approval begin market new drug market exist drug product new indication regulation prescribe manner drug manufacture package label advertise market distribute regulation impact pricing drug regulatory requirement assess report adverse impact effect drug clinical trial market drug call pharmacovigilance ability regulatory authority remove product market modify approve useslabele recall certain batch product national regulation phase prescription drug business price centralize fda fda responsible protect public health assure safety efficacy security human veterinary drug biological product medical device generally free market pricing center medicare medicaid services cms medicare include provision price drug elderly disabled indigent receive federal prescription benefit scheringplough commit comply voluntary good practice pharmaceutical research manufacturers america phrma trade industry group member marketing advertising practice include scheringplough key market united kingdom france germany italy regulation local country level additional regulation level european medicine agency emea pharmaceutical product regulate level national mutual recognition centralized regulatory procedure emea coordinate evaluation supervision majority medicinal product paneu market pricing system individual member state systemsagencie regulate price local level japan regulation pharmaceutical medical device agency pmda pmda regulate pharmaceutical medical device development postmarketing use japanese government regulate pricingreimbursement pharmaceutical product japan table content complicated pricing process include benchmark price western country canada select country increase pressure governmental body major market thirdparty payor pharmaceutical industry bring product market provide differentiation versus exist product lead expensive scientifically challenging clinical trial order generate type datum new product versus market comparator focus product differentiation reliance comparator datum accelerate new federal grant provide stimulus package comparative effectiveness review billion health information technology billion couple billion bonus payment medicare medicaid physicians hospital adopt health information technology improvement difficult predict speed change degree impact new spending pharmaceutical market brand pharmaceutical product description prescription pricing pressure refer pricing pressure item management discussion analysis financial condition result operation raw material raw material essential scheringploughs operation available adequate quantity number potential supplier energy expect available scheringplough sufficient quantity meet operating requirement seasonality certain scheringplough product particularly respiratory sun care product seasonal nature seasonal pattern material effect consolidated operation scheringplough environment date environmental matter material effect scheringplough operation financial position matter include compliance federal state local law discharge material environment protection environment climate change employee december scheringplough approximately employee worldwide approximately employee united states approximately employee outside united states available information scheringplough amendment report file furnish securities exchange commission sec available free charge scheringploughs web site soon reasonably practicable material electronically file sec scheringploughs internet address wwwscheringploughcom scheringplough begin practice quarter report available scheringploughs web site hour filing report file scheringplough sec read copy secs public reference room street washington information operation public reference room obtain call sec sec sec maintain internet site wwwsecgov contain report proxy information statement information issuer file electronically sec item risk factor scheringplough future operating result cash flow differ materially result describe risk uncertaintie relate scheringploughs business include discuss table content addition factor represent risk uncertainty cause actual result differ materially imply forwardlooke statement contain report key scheringplough product generate significant scheringplough profit cash flow event adversely affect market lead product material negative impact result operation cash flow scheringplough ability generate profit operate cash flow depend largely continued profitability schering plough cholesterol franchise consist vytorin zetia key product remicade temodar nasonex pegintron clarinex follistim claritin remeron nuvaring result scheringplough dependence key product event adversely affect product market product significant impact result operation cash flow event include loss patent protection increase cost associate manufacturing generic otc availability scheringplough product competitive product discovery previously unknown effect increase competition introduction new effective treatment discontinuation removal market product reason high risk fund invest research generate financial return development novel drug require significant expenditure low probability success high rate failure inherent research develop new drug treat disease result high risk fund invest scheringplough research program generate financial return risk profile compound fact research long investment cycle bring pharmaceutical compound discovery phase market decade failure occur point process include later process significant fund invest scheringplough success dependent successful development marketing new product subject substantial risk product appear promise development fail reach market numerous reason include follow finding ineffectiveness superior safety efficacy compete product harmful effect clinical preclinical testing failure receive necessary regulatory approval include delay approval new product new indication increase uncertainty time require obtain regulatory approval benefitrisk standard apply regulatory agency determine grant approval lack economic feasibility manufacturing cost factor preclusion commercialization proprietary right intellectual property protection innovation important contributor scheringplough profitability generic form scheringplough product introduce market result expiration patent cover scheringploughs product successful challenge scheringploughs patent atrisk launch generic version scheringplough product material negative effect result operation intellectual property protection critical scheringplough ability successfully commercialize product patent relate scheringplough significant product material importance scheringplough expiration successful challenge scheringplough patent cover product competitor introduce lowerpriced generic similar branded version product include scheringplough wellestablishe product generic manufacturer file abbreviate new drug application seek approval expiration applicable datum exclusivity allege patent list table content innovator new drug application invalid infringe unenforceable allegation commonly know paragraph certification innovator ability file suit generic manufacturer enforce patent generic manufacturer paragraph certification extensively challenge patent wide array innovative pharmaceutical anticipate trend continue recent year generic manufacturer launch generic version product ultimate resolution patent litigation commonly know atrisk product launch generic entry result loss significant portion sale downward pressure price scheringplough offer patent product refer legal proceeding item description pende intellectual property litigation additionally certain foreign government indicate compulsory license patent grant case national emergency diminish eliminate sale profit region negatively affect scheringploughs result operation recent court decision relate company patent potential legislation relate patent reform regulatory initiative result erosion intellectual property protection patent dispute costly prosecute defend adverse judgment result damage award increase royalty similar payment decrease sale patent position highly uncertain patent dispute pharmaceutical industry unusual adverse result patent dispute involve scheringploughs patent patent collaborator lead determination court patent infringe invalid andor unenforceable adverse determination lead scheringploughs loss market exclusivity adverse result patent dispute allege scheringplough infringe patent hold party lead determination court patent infringe valid enforceable adverse determination preclude commercialization schering plough product andor lead significant financial damage past ongoing infringement uncertainty surround patent litigation party settle patent dispute obtain license mutually agreeable term order decrease risk interruption manufacturing andor marketing product potential litigation scheringploughs intellectual property right exist litigation initiate party attempt abridge scheringplough right scheringplough ultimately successful particular dispute scheringplough incur substantial cost defend patent intellectual property right patent challenge hatchwaxman act item legal proceeding list current paragraph certification scheringplough product multijurisdictional regulation include establish scheringploughs ability price product negatively affect scheringplough sale profit margin scheringplough face increase pricing pressure globally manage care organization institution government agency program negatively affect scheringplough sale profit margin example medicare prescription drug improvement modernization act contain prescription drug benefit individual eligible medicare prescription drug benefit effective january result increase use generic increase purchasing power negotiating behalf medicare recipient turn result increase price pressure scheringplough product addition legislation concern price control trend adversely affect scheringplough sale profit margin trend include legislative regulatory action relate pharmaceutical pricing reimbursement health care reform initiative drug importation legislation involuntary approval medicine otc use trend include nongovernmental initiative practice consolidation customer manage care practice health care cost containment increasingly market approval reimbursement product prescriber practice policy thirdparty payor table content influence health technology assessment national institute health clinical excellence organization result government effort reduce health care expenditure payor effort reduce health care cost scheringplough face increase pricing pressure payor continue seek price discount respect scheringplough product country governmental agency strictly control directly indirectly price pharmaceutical product sell market cost control method include restriction physician prescription level patient reimbursement emphasis great use generic drug acrosstheboard price cut decrease revenue internationally acquisition obs scheringplough acquire market product pipeline project new therapeutic area include women health central nervous system carry unique risk uncertainty negative impact future result operation cash flow acquisition obs scheringplough acquire product additional therapeutic area therapeutic area present different risk profile include different benefit safety issue balance scheringplough regulator research development marketing decision unique product liability risk different patient prescriber priority different societal pressure add new therapeutic area strengthen scheringploughs business increase sale profit make combined company relevant patient prescriber diversify enterprise risk area positive outweigh additional risk particular therapeutic area result unanticipated cost significant adverse impact result operation cash flow market force continue evolve impact scheringplough ability sell product price scheringplough charge product number intermediary involve drug manufacturer scheringplough patient use drug intermediary impact patient ability prescriber ability choose pay particular drug adversely affect sale particular scheringplough drug intermediary include health care provider hospital clinic payor representative employer insurer manage care organization government supply chain pharmacist wholesaler example include payor require patient fail generic expensive brand drug reimburse effective brand product expensive payor increase patient copayment amount hospital stock administer generic product inpatient manage care organization penalize doctor prescribe outside approve formulary include brand product generic available pharmacist receive large revenue dispense generic drug brand drug intermediary require routinely provide transparent data patient compare effectiveness generic brand product disclose economic benefit tie steering patient require patient use generic product brand product government investigation involve scheringplough lead commencement civil andor criminal proceeding involve imposition substantial fine penalty injunctive administrative remedy include exclusion government reimbursement program rise investigation litigation government entity private party scheringplough predict future pende investigation subject lead judgment settlement involve significant monetary award restriction operation pricing sale marketing program arrangement relate business practice scheringplough participant health care industry increase scrutiny federal state regulatory investigative prosecutorial administrative entity entity include department table content justice attorney office office inspector general department health human service fda federal trade commission state attorney general office health care law certain governmental entity operate include federal state antikickback statute statutory common law false claim law construe broadly court permit government entity exercise significant discretion event governmental entity believe wrongdoing occur institute civil criminal proceeding resolve unfavorably subject scheringplough substantial fine penalty injunctive administrative remedy include exclusion government reimbursement program addition adverse outcome government investigation prompt government entity commence investigation scheringplough cause entity private party bring civil claim scheringplough predict investigation affect marketing practice sale result material adverse impact schering plough result operation cash flow financial condition business number governmental entity inquiry initiate investigation time disclosure relate enhance clinical trial include letter congress investigation state attorney general office request information attorney offices department justice regardless merit outcome investigation government investigation costly divert management attention scheringplough business result substantial damage scheringplough reputation item legal proceeding litigation investigation relate merckscheringplough cholesterol joint venture information merckscheringplough cholesterol joint venture enhance clinical trial relate matter legal matter adverse outcome negatively affect scheringploughs result operation cash flow financial condition business unfavorable outcome pende litigation matter future litigation include litigation concern product pricing security law violation product liability claim erisa matter patent intellectual property dispute antitrust matter preclude commercialization product negatively affect profitability exist product subject scheringplough substantial fine penalty injunctive administrative remedy include exclusion government reimbursement program result materially adversely affect scheringploughs result operation cash flow financial condition business aggressive plaintiff counsel file litigation wide variety allegation medium attention negative discussion efficacy safety product stock price volatile allegation groundless scheringplough need expend considerable fund resource respond litigation refer legal proceeding item description significant pende litigation issue concern merckscheringplough cholesterol joint venture clinical trial material adverse effect joint venture sale vytorin zetia turn material adverse impact scheringplough financial condition item legal proceeding litigation investigation relate merckscheringplough cholesterol joint venture information merckscheringplough cholesterol joint venture enhance clinical trial relate matter significant negative medium surround release enhance result merckscheringplough cholesterol joint venture enhance seas clinical trial result review vytorin zetia receive additional media attention connection clinical table content trial lead reduced sale affect enrollment clinical trial current future investigation analysis enhance sea clinical trial data agency litigation concern sale promotion product security class action litigation relate matter resolve unfavorably scheringplough joint venture material adverse effect scheringplough result operation cash flow financial position scheringplough party act behalf subject governmental regulation failure comply cost compliance regulation adversely affect scheringploughs result operation cash flow financial position manufacture research practice scheringplough party act behalf meet stringent regulatory standard subject regular inspection cost regulatory compliance include associate compliance failure materially affect scheringploughs result operation cash flow financial position failure comply regulation include pharmacovigilance reporting requirement standard relate clinical laboratory manufacturing practice result suspension termination clinical study delay failure obtain approval drug seizure recall drug suspension revocation authority necessary production sale drug withdrawal approval fine civil criminal sanction scheringplough subject regulation include environmental health safety labor regulation development follow regulatory approval adversely affect sale scheringplough product product reaches market certain development follow regulatory approval include result postmarkete phase trial decrease demand scheringplough product include follow rereview product market new scientific information evolution scientific theory recall loss marketing approval product market change government standard public expectation safety efficacy labeling change great scrutiny advertising promotion past year clinical trial postmarkete surveillance certain market drug competitor industry raise safety concern lead recall withdrawal adverse labeling market product clinical trial postmarkete surveillance certain market drug raise concern prescriber patient relate safety efficacy pharmaceutical product general negatively affect sale product addition increase scrutiny outcome clinical trial lead increase volatility market reaction matter attract litigation basis litigation groundless considerable resource need respond addition follow wake product withdrawal company significant safety issue health authority fda emea pmda increase focus safety assess benefitrisk balance drug health authority appear cautious making decision approvability new product indication review select product market add uncertainty regulatory process great regulatory scrutiny especially advertising promotion particular directtoconsumer advertising previously unknown effect discover increase negative publicity know effect scheringplough product significantly reduce demand product require scheringplough action negatively affect sale include remove product market restrict distribution apply labeling change current table content environment pharmaceutical company operate scheringplough risk product liability claim product new product technological advance develop scheringploughs competitor negatively affect sale scheringplough operate highly competitive industry scheringplough compete large number multinational pharmaceutical company biotechnology company generic pharmaceutical company scheringploughs competitor conduct research development area serve scheringplough current product product scheringplough process develop competitive development impact scheringplough include technological advance patent grant new product develop competitor new exist generic prescription andor otc product compete product scheringplough merckscheringplough cholesterol joint venture addition possible doctor patient provider favor product offer competitor safety efficacy pricing reimbursement characteristic result scheringplough unable maintain sale product competition party difficult scheringplough acquire license new product product candidate regardless stage development enter transaction term permit scheringplough generate positive financial impact scheringplough depend acquisition inlicense arrangement source new product opportunity obtain license new product limit secure right typically require substantial amount fund substantial resource commitment scheringplough compete opportunitie company party great financial resource great ability resource commitment scheringplough able acquire license new product adversely impact scheringplough prospect scheringplough difficulty acquire license new product acceptable term secure right new product scheringplough substantial financial resource commitment limit ability produce positive financial impact transaction scheringplough rely thirdparty relationship key product conduct change circumstance party adversely impact business scheringplough relationship party scheringplough depend key product party compete scheringplough interest align interest scheringplough notwithstanding contract scheringplough party scheringplough able control influence conduct party circumstance affect adversely impact scheringplough relationship longstanding party work scheringplough work evolve priority alignment change time new issue develop anticipate time contract negotiate new issue relate uncertainty contract adversely impact scheringplough scheringplough global operation expose scheringplough additional risk adverse event material negative impact result operation majority scheringplough operation outside acquisition obs late scheringploughs global operation prescription pharmaceutical animal health increase acquisition recently complete purchase obs expand size scale scope scheringplough global operation risk inherent conduct global business include change medical reimbursement policy program price restriction key market table content multiple regulatory requirement restrict scheringploughs ability manufacture sell product key market trade protection measure import export licensing requirement diminish protection intellectual property country possible nationalization expropriation addition change scheringplough business political position instability disruption destruction significant geographic region regardless cause include war terrorism riot civil insurrection social unrest natural manmade disaster include famine flood fire earthquake storm disease integration business scheringplough obs create combine company complex process subject unforeseen development adverse impact result future operation company combine workforce scheringplough obs continue face uncertainty completion integration phase cultural integration particularly transatlantic transaction complex year substantial progress complete integration phase obs acquisition quickly possible difficult predict long integration phase workforce company learn use new process work integrate streamlined employee new combine company past work usbased global company applicable regulatory requirement different number respect substantial effort facilitate smooth execution integration include thorough training transparent motivational employee communication increase risk slow execution work process repeat execution achieve quality standard reputational harm event compliance failure new complex regulatory requirement failure inadvertent event adverse impact result future operation acquisition obs expand scheringploughs animal health business worldwide increase risk negative event animal health industry negative impact future result operation acquisition obss animal health business scheringplough global animal health business significant business segment combine company future sale key animal health product adversely impact number risk factor include certain risk specific animal health business example outbreak disease carry animal bovine spongiform encephalopathy bse mad cow disease lead widespread death precautionary destruction reduce consumption demand animal adversely impact scheringploughs result operation outbreak highly contagious disease near scheringplough main production site require scheringplough immediately halt production vaccine site force scheringplough incur substantial expense procure raw material vaccine risk specific animal health include epidemic pandemic government procurement pricing practice weather global agribusiness economic event animal health segment scheringplough business significant impact event future result operation significant table content acquisition obs increase scheringplough biologics human animal health product offering include animal health vaccine biologic carry unique risk uncertainty negative impact future result operation successful development testing manufacturing commercialization biologic particularly human animal health vaccine long expensive uncertain process unique risk uncertaintie biologic include limited access supply normal diseased tissue sample cell line pathogen bacteria viral strain biological material addition government regulation multiple jurisdiction european state result restrict access transport use material scheringplough lose access sufficient source material tight restriction impose use material scheringplough able conduct research activity plan incur additional development cost development manufacturing marketing biologic subject regulation fda emea regulatory body regulation complex extensive regulation applicable pharmaceutical product example biologic license application include preclinical clinical trial datum extensive datum manufacturing procedure require human vaccine candidate fda approval release manufacture lot manufacture biologic especially large quantity complex require use innovative technology handle living microorganism lot approve biologic undergo thorough testing identity strength quality purity potency manufacturing biologic require facility specifically design validate purpose sophisticated quality assurance quality control procedure necessary slight deviation manufacturing process include fill labeling packaging storage shipping quality control testing result lot failure product recall spoilage change manufacturing process scheringplough require provide preclinical clinical datum show comparable identity strength quality purity potency product change biologic frequently costly manufacture production ingredient derive live animal plant material biologic synthetically particular keeping demand vaccine difficult complexity produce vaccine use biologically derive ingredient lead allegation harm include infection allergic reaction closure product facility possible contamination event result substantial cost currently process submission approval generic biologic base abbreviate datum package show sameness approve biologic public dialogue fda congress scientific statutory basis product know biosimilar followon biologic approve market scheringplough certain congress create statutory pathway approval biosimilar schere plough predict impact approval biosimilar sale scheringplough product europe emea issue guideline approve biological product abbreviate pathway biosimilar approve europe biosimilar version scheringplough product approve europe negative effect sale product scheringplough expose market risk fluctuation currency exchange rate interest rate scheringplough operate multiple jurisdiction virtually sale denominate currency local jurisdiction additionally scheringplough enter enter acquisition licensing borrowing financial transaction rise currency interest rate exposure table content scheringplough certainty foresee mitigate adverse fluctuation fluctuation currency exchange rate interest rate negatively affect scheringploughs result operation financial position cash flow order mitigate adverse impact market fluctuation scheringplough time time enter hedge agreement hedge agreement currency option interest rate swap limit exposure exchange rate interest rate fluctuation attempt mitigate risk costly successful current stock market credit market condition extremely volatile unpredictable difficult predict condition continue worsen condition impact scheringplough impact material scheringplough exposure different industry counterpartie include commercial bank investment bank supplier customer include wholesaler manage care organization government unstable unstable current economic environment instability impact party ability fulfill contractual obligation scheringplough limit place burdensome condition future transaction scheringplough customer reduce spending time economic uncertainty possible supplier negatively impact event result material adverse impact operation result operation scheringplough currently plan access equity debt market meet capital liquidity need constriction volatility market restrict future flexibility unforeseen capital liquidity need arise current condition result severe downward pressure stock credit market reduce return available invest corporate cash reduce return investment hold pension plan potentially increase funding obligation severe sustained material adverse impact scheringplough result operation financial position cash flow insurance coverage product liability limit cost prohibitive unavailable scheringplough maintain insurance coverage deductible selfinsurance reflect market condition include cost availability exist time write relationship insurance coverage selfinsurance vary accordingly certain product thirdparty insurance increasingly cost prohibitive available limited term past coverage unavailable schering plough selfinsure substantially risk relate product liability availability commercial insurance restrictive scheringplough continually assess good way provide insurance need scheringplough subject evolve complex tax law result additional liability affect result operation scheringplough subject evolve complex tax law jurisdiction operate significant judgment require determine scheringploughs tax liability scheringplough tax return periodically examine tax authority schere plough believe accrual tax contingency adequate open year base past experience interpretation tax law judgment potential action tax authority complexity tax contingency ultimate resolution tax matter result payment great amount accrue addition scheringplough impact change tax law include tax rate change change law relate remittance foreign earning new tax law revise tax law interpretation domestic foreign jurisdiction table content item unresolved staff comment item property scheringplough corporate global pharmaceutical headquarters locate kenilworth new jersey scheringploughs animal health global headquarters locate boxmeer netherland principal research facility locate kenilworth union summit new jersey palo alto california nebraska animal health principal research facility outside locate netherlands scotland principal manufacturing facility follow location product type belgium pharmaceutical brazil pharmaceuticals animal health cleveland tennessee usa consumer product france pharmaceuticals ireland pharmaceutical consumer product animal health kenilworth new jersey usa pharmaceuticals consumer product mexico pharmaceutical millsboro delaware usa animal health netherlands pharmaceuticals animal health omaha nebraska usa animal health puerto rico pharmaceuticals research triangle park north carolina usa pharmaceuticals singapore pharmaceuticals scheringplough own majority property general property adequately maintain suitable purpose discuss detail certain scheringplough manufacturing site operate capacity april scheringplough announce productivity transformation program reduction number plant worldwide goal create focused highefficiency network plant analysis optimal configuration plant ongoing item legal proceeding material pende legal proceeding ordinary routine litigation incidental business scheringplough corporation subsidiary property subject disclose additional information legal proceeding include important financial information find note legal environmental regulatory matter contain item financial statement supplementary datum patent matter describe patent trademark intellectual property right item business intellectual property protection critical scheringplough ability successfully commercialize product innovation potential litigation scheringploughs intellectual property right exist initiate party attempt abridge scheringplough right scheringplough protect right patent matter describe potential material effect schere plough table content patent challenge hatchwaxman act scheringplough currently believe pende paragraph certification proceeding hatchwaxman act material frequently medium investor interest proceeding scheringplough list pende proceeding quarter currently follow pende july scheringplough licensor cancer research technology limit file patent infringement action company seek approval generic version certain strength temodar capsule trial schedule begin march district court district delaware march scheringplough entity jointly own merck file patent infringement action company seek approval generic version zetia september date scheringplough file patent infringement action company seek approval generic version clarinex tablets clarinex reditab clarinex clarinex scheringplough settle majority company continue litigate remain defendant term settlement generic version clarinex reditab clarinex clarinex launch early january generic version clarinex tablet launch early july assume certain condition meet february scheringplough licensor file patent infringement action company seek approval generic version integrilin awp litigation investigation scheringplough continues respond exist new litigation certain state private payor investigation department health human services department justice state industry scheringplough practice average wholesale price awp scheringplough cooperating investigation litigation investigation relate awp pharmaceutical company certain drug improperly exceed average price pay provider consequence result unlawful inflation certain reimbursement drug state program private payor base awp complaint allege violation federal state law include fraud medicaid fraud consumer protection violation claim majority case plaintiff seek class certification case class certify outcome litigation investigation include substantial damage imposition substantial fine penalty injunctive administrative remedy security class action litigation federal security litigation follow scheringploughs announcement fda conduct inspection scheringplough manufacture facility new jersey puerto rico issue report cite deficiency concern compliance current good manufacturing practice lawsuit file scheringplough certain name officer lawsuit allege defendant violate federal security law allegedly fail disclose material information make material misstatement specifically allege schering plough fail disclose allege risk new drug application clarinex delay result manufacturing issue allege scheringplough fail disclose allege depth severity manufacturing issue complaint consolidate action district court district new jersey consolidated amend complaint file october purport represent class shareholder purchase share scheringplough stock february complaint seek table content compensatory damage behalf class court certify shareholder class october notice pendency class action send member class july february court sign order preliminarily approve settlement agreement propose settlement agreement schedule present final approval hearing june erisa litigation march scheringplough serve putative class action complaint file district court new jersey allege scheringplough retire chairman ceo president richard jay kogan scheringploughs employee saving plan plan administrator current director certain corporate officer breach fiduciary obligation certain participant plan complaint seek damage loss allegedly suffer plan complaint dismiss june plaintiff appeal august court appeal circuit reverse dismissal district court matter remand district court proceeding kdur antitrust litigation scheringplough settle patent litigation upshersmith inc upshersmith esi lederle inc lederle relate generic version kdur scheringploughs longacte potassium chloride product supplement cardiac patient lederle upsher smith file abbreviate new drug application follow commencement ftc administrative proceeding allege anti competitive effect settlement resolve scheringplough favor allege class action suit file federal state court behalf direct indirect purchaser kdur scheringplough upshersmith lederle suit claim violation federal state antitrust law state statutory common law cause action suit seek unspecified damage february special master recommend district court district new jersey dismiss class action lawsuit summary judgment thirdparty payor action purport class action litigation file follow announcement settlement massachusetts investigation plaintiff action seek damage behalf thirdparty payor result allegation offlabel promotion improper payment physician issue massachusetts investigation litigation investigation relate merckscheringplough cholesterol joint venture background january merckscheringplough cholesterol joint venture announce result enhance clinical trial effect combination ezetimibe highdose simvastatin simvastatin atherosclerotic process patient heterozygous familial hypercholesterolemia july merckscheringplough cholesterol joint venture announce result sea clinical trial simvastatin ezetimibe aortic stenosis litigation investigation respect matter relate clinical trial disclose prior filing refer legal proceeding item scheringplough item legal proceeding form period end march june september information recent cholesterol clinical trial form period end june september scheringplough cooperate fully investigation respond request information scheringplough intends vigorously defend lawsuit file relate enhance study investigation inquiry date file scheringplough joint venture andor joint venture partner merck receive number governmental inquiry subject number investigation inquiry relate enhance clinical trial include table content letter congress include subcommittee oversight investigation house committee energy commerce rank minority member senate finance committee collectively seek combination witness interview document information variety issue relate merckscheringplough cholesterol joint venture enhance clinical trial include subpoena state official include state attorney general request information attorney department justice seek similar information document addition scheringplough receive letter subcommittee oversight investigation house committee energy commerce seek certain information document relate seas clinical trial matter scheringplough merck joint venture cooperating investigation respond inquiry january initial release enhance datum fda state review result enhance trial january fda announce result review fda state follow year treatment carotid artery thickness increase vytorin group simvastatin group difference change carotid artery thickness group statistically significant level ldl cholesterol decrease vytorin group decrease simvastatin group difference reduction ldl cholesterol group statistically significant fda state result enhance change position elevate ldl cholesterol risk factor cardiovascular disease lower ldl cholesterol reduce risk cardiovascular disease fda state pende result improveit clinical trial patient stop take vytorin cholesterol lower medication talk doctor question litigation scheringplough continues respond exist new litigation include civil class action lawsuit allege common law state consumer fraud claim connection scheringplough sale promotion merckscheringplough joint venture product vytorin zetia putative shareholder security class action lawsuit officer name defendant allege false misleading statement omission scheringplough representative relate timing disclosure concern enhance result allegedly violation section securities exchange act putative shareholder security class action lawsuit officer director name allege material misstatement omission relate enhance result offer document connection scheringplough security offering allegedly violation security act include section putative class action suit allege scheringplough certain officer director breach fiduciary duty erisa seek damage loss allegedly suffer plan shareholder derivative action allege board director breach fiduciary obligation relate timing release enhance result letter behalf single shareholder request board director investigate allegation litigation describe warrant bring appropriate legal action behalf scheringplough tax matter october irs auditor assert interest rate swap scheringplough enter unrelated party recharacterize loan affiliate company result additional tax liability tax year september scheringplough payment irs million income tax million interest scheringplough file refund claim tax interest irs december follow irss denial scheringplough claim refund scheringplough file suit district court district new jersey refund tax interest refund litigation try newark district court decision render scheringplough tax reserve adequate cover abovementione payment table content pende administrative obligation connection settlement investigation department justice attorney office eastern district pennsylvania scheringplough enter fiveyear corporate integrity agreement cia cia amend august connection settlement massachusetts investigation commence new fiveyear term failure comply obligation cia result financial penalty date scheringplough believe comply obligation matter product liability beginning number complaint file jurisdiction assert claim organon usa inc organon pharmaceuticals usa inc organon international organon scheringplough corporation arise organon marketing sale nuvare combine hormonal contraceptive vaginal ring plaintiff contend organon scheringplough fail adequately warn allege increase risk venous thromboembolism vte pose nuvare andor downplay risk vte plaintiff seek damage injury allegedly sustain product use include alleged death heart attack stroke majority case currently pende federal multidistrict litigation venue missouri new jersey state court case pende state french matter base complaint french competition authority competitor france pursuant court order french competition authority obtain document french subsidiary scheringplough relate subutex product subsidiary market sell resolution matter adverse french subsidiary result imposition civil fine injunctive administrative remedy july juge des libert dtention order annulment search seizure procedural ground july french authority appeal order french supreme court april competitor request interim relief portion grant french competition authority december interim relief require scheringploughs french subsidiary publish specialized newspaper information include generic quantitative qualitative composition pharmaceutical form substitutable subutex february paris court appeal confirm decision french competition authority january french supreme court confirm decision french competition authority item submission matter vote security holder applicable executive officer registrant list executive officer corporate officer scheringplough february indicate hold position indicate past year officer serve year successor duly appoint table content title robert bertolini executive vice president chief financial officer john carroll vice president global internal audits ron cheeley senior vice president global human resource carrie cox executive vice president president global pharmaceuticals william creelman vice president tax fred hassan chairman chief executive officer maria teresa hilado vice president treasurer steven koehler vice president controller thomas koestler phd executive vice president president scheringplough research institute raul kohan senior vice president president intervetscheringplough animal health ian mcinne phd senior vice president president global supply chain lori queisser senior vice president global compliance business practice thomas sabatino executive vice president general counsel karl salnoske vice president chief information officer brent saunder senior vice president president consumer health care susan ellen wolf corporate secretary associate general counsel vice president governance officer define rule securities exchange act bertolini join scheringplough executive vice president chief financial officer bertolini partner pricewaterhousecoopers carroll join scheringplough vice president global internal audits carroll vice president general auditor american standard company general auditor american standard company cheeley join scheringplough senior vice president global human resources cheeley group vice president global compensation benefit pharmacia corporation cox join scheringplough executive vice president president global pharmaceuticals cox executive vice president president global prescription business pharmacia corporation creelman join scheringplough vice president tax creelman senior tax counsel pfizer creelman assistant vice president international tax cigna corporation hassan join scheringplough chairman board chief executive officer hassan chairman board chief executive officer pharmacia corporation hilado join scheringplough vice president treasurer hilado assistant treasurer general motors corporation january april chief financial officer gmac commercial finance koehler join scheringplough vice president controller koehler senior vice president chief financial officer treasurer vice president chief financial officer treasurer corporate secretary medicine company table content koestler name executive vice president president scheringplough research institute september koestler executive vice president global development scheringplough research institute september executive vice president scheringplough research institute senior vice president global regulatory affair pharmacia corporation kohan name senior vice president president intervetscheringplough animal health october kohan deputy head animal health senior vice president corporate excellence administrative service scheringplough corporation end october kohan senior vice president president animal health february october group head global specialty operation president animal health mcinne name senior vice president president global supply chain february mcinne join scheringplough senior vice president global supply chain mcinne senior vice president global supply chain pharmacia corporation executive vice president supply chain watson pharmaceuticals inc queisser join scheringplough february senior vice president global compliance business practice queisser vice president chief compliance officer eli lilly company october february sabatino join scheringplough executive vice president general counsel sabatino senior vice president general counsel baxter international inc salnoske join scheringplough vice president chief information officer salnoske ceo adaptive trade saunder join scheringplough senior vice president global compliance business practice saunders partner pricewaterhousecooper prior join scheringplough wolf name vice president corporate secretary associate general counsel hold position schere plough law department item market registrant common equity relate stockholder matter issuer purchase equity security principal market scheringplough common stock new york stock exchange additional information require item incorporate reference table caption quarterly datum unaudite item financial statement supplementary datum follow table provide information respect purchase scheringplough common share fourth quarter issuer purchase equity security total number aximum number share purchase share average publicly purchase total number price pay announce plan plan period share purchase share program programs october october november november december december total october december table content share include table represent share deliver scheringplough option holder payment exercise price tax withholding obligation connection stock option stock award pursuant scheringploughs stock incentive program performance graph comparison cumulative total return scheringplough corporation composite peer group index graph assume investment december reinvestment dividend scheringplough common share index composite peer group major usbased pharmaceutical company abbott laboratories bristolmyers squibb company johnson johnson eli lilly company merck pfizer inc wyeth table content item select financial datum million share figure percentage operate result net sale equity income incomeloss income taxis cumulative effect change accounting principle net incomeloss net incomeloss available common shareholder dilute earningsloss common share basic earningsloss common share research development expense acquire inprocess research development depreciation amortization expense financial position cash flow property net total asset longterm debt shareholder equity capital expenditure financial statistic net incomeloss percent net sale return average shareholder equity net book value common share datum cash dividend common share cash dividend pay common share cash dividend pay preferred share average share outstanding calculate dilute earningsloss common share average share outstanding calculate basic earningsloss common share common share outstanding yearend operating result financial information reflect operation obs business subsequent acquisition november include impact purchase accounting accordance sfas business combination include special acquisitionrelate charge manufacture streamlining cost respectively note special acquisitionrelate charge manufacture streamline additional information charge incur special charge incur million include litigation charge million employee termination cost million asset impairment charge million special charge incur include million employee termination cost million asset impairment relate charge increase longterm debt compare primarily reflect finance obs acquisition table content assume conversion mandatory convertible preferred stock approximately million common share assume conversion mandatory convertible preferred stock approximately million common share million common share million common share mandatory convertible preferred stock convert common share item management discussion analysis financial condition result operation executive summary overview scheringplough scheringplough innovationdriven sciencecentere global health care company scheringplough discover develop manufacture pharmaceutical customer market prescription animal health consumer research development activity direct prescription product important application central research development platform animal health product consumer health care product scheringplough access external innovation partner inlicense acquisition customer market strategy focus science soon fred hassan elect chairman board chief executive officer scheringplough corporation initiate sixtoeight year strategic plan call action agenda key component action agenda apply science meet unmet medical need core strategy scheringplough invest substantial fund scientific research goal create therapy treatment address important unmet medical need commercial value consistent core strategy scheringplough increase investment research development scheringplough successful advance pipeline late stage project require sizable resource complete scheringplough continue develop laterphase pipeline compound golimumab sugammadex thrombin receptor antagonist vicriviroc boceprevir asenapine progress early pipeline include drug candidate wide range therapeutic area key component action agenda focus build longterm value shareholder patient rely scheringploughs drug longerterm focus include concurrent emphasis grow sale discipline cost control invest research development future early hassan new management team recruit applied action agenda stabilizing repair turn scheringplough scheringplough encounter challenge early decade prior management team currently scheringplough continue work fourth phase action agenda fourth build base phase scheringplough continue focus strategy value creation broad past year sale scheringplough pharmaceutical product array therapeutic area show strong growth compare prior period pharmaceutical company scheringplough pharmaceutical sale marketing activity expand new market geographic diversity add growth make performance sensitive geographic area substantial progress integration organon bioscience obs purchase akzo nobel late acquisition transformative give scheringplough key new pipeline project include asenapine schizophrenia bipolar disease sugammadex reverse deep anesthesia key product new therapeutic area women health central nervous system position leader animal health combine scheringplough animal health intervet leadership position animal vaccine intervet earlystage innovation capability human vaccine nobilon table content additional stateoftheart biologic capabilitie substantial expansion company geographic footprint significant talent include key research development function april scheringplough announce productivity transformation program ptp goal program include ongoing integration ob create lean strong company support scheringplough goal build longterm high performance despite current challenging pharmaceutical industry environment particular challenge face scheringplough program target saving billion annualize basis design reduce avoid cost increase productivity total target saving approximately billion anticipate accomplished end balance achieve target saving envision program include result previously announce obs integration synergy program scheringplough anticipate invest new highpriority clinical trial pursuit strategic opportunity include product launch anticipate natural cost growth action agenda scheringplough continue work enhance infrastructure upgrade process system strengthen talent effort implement companywide basis scheringplough focus especially research development support scheringplough sciencebase business pharmaceutical industry increase political regulatory pressure particularly united states scheringplough merckscheringplough cholesterol joint venture encounter specific challenge explain detail item legal proceeding litigation investigation relate merckscheringplough cholesterol joint venture strength scheringplough build early phase action agenda include diversified group product customer segment geographic area highly experienced executive team helpful weather current future challenge include relate merckscheringplough cholesterol joint venture result highlight scheringplough performance follow scheringplough net sale billion increase billion percent compared increase net sale primarily contribution product ob net sale outside total billion approximate percent consolidate net sale net income available common shareholder billion include gain divestiture certain animal health product increase sale pharmaceutical product remicade temodar nasonex increase sale animal health segment contribute favorably scheringplough overall operating result overall operating result benefit increase sale ob product global combine net sale scheringplough cholesterol franchise product vytorin zetia decrease percent compare combine net sale product vytorin zetia decrease percent compare strategic alliance typical pharmaceutical industry scheringplough license manufacturing marketing andor distribution right certain product manufacture market andor distribute product own pursuant license joint venture arrangement time party involve additional factor relate party outside control scheringplough table content create positive negative impact scheringplough vytorin zetia remicade subject arrangement key scheringplough current business financial performance addition potential strategic alternative impact change control provision arrangement result vytorin zetia acquire merck remicade golimumab revert centocor change control provision relate vytorin zetia include contract merck file exhibit change control provision relate remicade golimumab contain contract centocor file exhibit cholesterol franchise scheringploughs cholesterol franchise product vytorin zetia manage joint venture scheringplough merck treatment elevate cholesterol level market outside japan zetia scheringplough novel cholesterol absorption inhibitor vytorin combination zetia zocor simvastatin statin medication develop merck financial commitment compete cholesterolreduction market share merck profit sale vytorin zetia share merck operating result joint venture merck record equity method accounting cholesterolreduction market single large pharmaceutical category world vytorin zetia compete market global total combine sale vytorin zetia decrease percent compare total combine sale vytorin zetia decline percent compare total combine sale vytorin zetia outside increase percent compare december total combine prescription share vytorin zetia versus december percent percent past scheringploughs profitability largely dependent performance cholesterol franchise performance cholesterol franchise material scheringplough product diversity strong obs acquisition development scheringplough product dependence cholesterol franchise lessening japan include joint venture merck japanese market bayer healthcare comarketing scheringploughs cholesterolabsorption inhibitor zetia approve japan april monotherapy coadministere statin use patient hypercholesterolemia familial hypercholesterolemia homozygous sitosterolemia zetia launch japan june scheringploughs sales zetia japan comarkete agreement bayer healthcare recognize net sale include pharmaceutical license arrangement centocor remicade prescribe treatment inflammatory disease rheumatoid arthritis early rheumatoid arthritis psoriatic arthritis crohns disease ankylose spondylitis plaque psoriasis ulcerative colitis remicade scheringplough secondlargest market pharmaceutical product line cholesterol franchise remicade license manufactured centocor inc johnson johnson company scheringplough exercise option contract centocor license right develop commercialize golimumab fully human monoclonal antibody file approval europe scheringplough exclusive marketing right product outside japan certain asian market december scheringplough centocor revise distribution agreement development commercialization distribution remicade golimumab extend scheringploughs right exclusively market remicade match duration scheringplough exclusive marketing right golimumab effective regulatory approval golimumab scheringploughs marketing right product extend year commercial sale golimumab centocor receive progressively increase share profit schere plough distribution product scheringplough marketing territory share profit remain fixed remainder term change duration remicade marketing right profit share arrangement product table content condition approval golimumab grant prior september scheringplough independently develop market golimumab crohns disease indication territory option centocor participate addition scheringplough centocor agree utilize autoinjector device commercialization golimumab agree share development cost manufacture sale marketing scheringplough support commercialize product manufacturing sale marketing effort scheringplough move forward additional investment enhance infrastructure business include capital expenditure drug development process product move drug discovery pipeline market information technology system postmarkete study monitor scheringplough continually review business include manufacturing operation identify action enhance longterm competitiveness scheringplough manufacturing cost base relatively fix action significantly reduce scheringploughs manufacturing infrastructure include specific reduction number scheringplough manufacturing facility productivity transformation program involve complex issue result shift product manufacturing plant year construction regulatory requirement include revalidation registration requirement future event decision lead asset impairment relate cost regulatory competitive environment scheringplough subject jurisdiction national state local regulatory agency regulatory compliance complex costly impact timing need bring new drug market market drug new indication scheringplough engage clinical trial research country world research activity comply stringent regulatory standard subject inspection local country regulatory authority scheringplough subject pharmacovigilance reporting requirement country jurisdiction include member states clinical trial postmarkete surveillance certain market drug competitor industry raise safety concern lead recall withdrawal adverse labeling market product number intermediary involve drug manufacturer scheringplough patient use drug intermediary impact patient ability prescriber ability choose pay particular drug intermediary include health care provider hospital clinic payor representative employer insurer manage care organization government supply chain pharmacist wholesaler scheringploughs pharmaceutical product subject increasingly competitive pricing certain intermediary include manage care group institution government agency seek price discount international market scheringplough operate environment governmentmandate costcontainment program price sale marketing program arrangement relate business practice scheringplough participant health care industry continue scrutiny federal state regulatory investigative prosecutorial administrative entity market pharmaceutical product competitive scheringplough operation affect technological advance competitor industry consolidation patent grant competitor loss patent protection challenge competitor competitive combination product new product competitor new information clinical trial market product postmarkete surveillance generic competition scheringplough product mature obs acquisition november scheringplough acquire obs purchase price approximately euro billion cash approximately billion table content commence acquisition date obss asset acquire liability assume result obss operation include scheringplough consolidated financial statement approximately onehalf month result operation relate obs include scheringplough statement consolidated operation year end december impact purchase accounting result follow noncash charge acquire inprocess research development iprd onetime charge approximately billion amortization inventory adjust fair value approximately billion charge cost sale million million amortization acquire intangible asset adjust fair value billion amortize weight average life year cost sale million million incremental depreciation relate adjustment fair value property plant equipment approximately million depreciate primarily cost sale live applicable property million million discussion operating result result operation discuss include obss product sale expense certain noncash charge relate purchase accounting associate obs acquisition net sale consolidate net sale billion increase billion percent compare consolidated net sale include billion net sale product ob increase primarily acquisition obs november foreign exchange estimate favorable impact sale acquisition obs great proportion schering plough sale denominate euros net sale outside approximately percent consolidated net sale consolidate net sale billion increase billion percent compare consolidated net sale include million net sale product obs relate period subsequent acquisition increase primarily reflect growth sale volume remicade temodar nasonex avelox contribution animal health consumer health care estimate favorable impact percent foreign exchange significant portion net sale major pharmaceutical health care product distributor major retail chain consequently net sale quarterly growth comparison affect fluctuation buy pattern major distributor retail chain trade buyer fluctuation result seasonality pricing wholesaler retail trade buying decision change overall demand factor factor addition fluctuation sale pharmaceutical product subject increase pricing pressure manage care group institution government agency group seek discount scheringplough pharmaceutical manufacturer market require provide statutorily define rebate government agency order participate medicaid program veterans health care program governmentfunde program medicare prescription drug improvement modernization act contain prescription drug benefit individual eligible medicare prescription drug benefit effective january result increase use generic increase purchasing power negotiating behalf medicare recipient international market scheringplough operate environment government mandate costcontainment program place restriction physician prescription level patient reimbursement emphasize great use generic drug enact acrosstheboard price cut method control cost table content net sale year end december follow incre ase dec rease dollar millions prescription pharmaceutical remicade nasonex temodar pegintron clarinexaerius follistimpuregon nuvare claritin avelox integrilin caelyx rebetol zemuron remeron intron subutexsuboxone asmanex pharmaceutical animal health consumer health care otc foot care sun care consolidate net sale product acquire obs acquisition november meaningful percentage sale prescription pharmaceutical total billion billion percent increase compare include billion million net sale relate organon human health business obs sale prescription pharmaceutical total billion billion percent increase compare international net sale remicade drug treatment immunemediate inflammatory disorder rheumatoid arthritis early rheumatoid arthritis psoriatic arthritis crohns disease ankylose spondylitis plaque psoriasis ulcerative colitis percent billion compare drive continued market growth expand penetration certain indication favorable impact foreign exchange international net sale increase percent billion compare great demand expand use indication favorable impact foreign exchange remicade antitnf antibody market schering plough outside japan certain asian market competitive product indication refer introduce table content global net sale nasonex nasal spray oncedaily corticosteroid nasal spray allergy rise percent billion compare increase sale international market percent billion compare product capture great international market share competitive product introduce global net sale temodar treatment certain type brain tumor increase percent billion compare increase sale geographic region global net sale increase percent million compare increase sale geographic market include japan product launch september temodar lose patent exclusivity global net sale pegintron powder injection pegylate interferon product treat hepatitis essentially flat compare include favorable impact foreign exchange global net sale increase percent million compare high sale latin america emerge market europe temper low sale japan increase competition decrease market size global net sale clarinex market aerius country outside treatment seasonal outdoor allergy yearround indoor allergy decrease percent million compare primarily low sale united states global net sale increase percent million compare primarily high sale international market global net sale follistimpuregon recombinant folliclestimulate hormone treat infertility million million represent sale date obs acquisition november december follistimpuregon lose patent exclusivity global net sale nuvare contraception product million million represent sale date obs acquisition november december international net sale prescription claritin increase percent million compare primarily high sale japan favorable foreign exchange sale increase percent million compare reflect growth latin america asia pacific japan net sale avelox fluoroquinolone antibiotic treatment certain respiratory skin infection market scheringplough result license agreement bayer decrease percent million compare reflect decline respiratory tract infection market net sale increase percent million compare million primarily result increase market share global net sale integrilin injection glycoprotein platelet aggregation inhibitor treatment patient acute coronary syndrome sell primarily scheringplough decrease percent million compare sale increase percent million compare international net sale caelyx treatment ovarian cancer metastatic breast cancer kaposis sarcoma increase percent million compare primarily high sale europe favorable foreign exchange sale increase percent million compare primarily increase sale latin america favorable impact foreign exchange global net sale rebetol capsule use combination pegintron intron treat hepatitis decrease percent million compare low sale japan continue generic competition global net sale decrease percent million compare lower patient enrollment japan increase generic competition table content global net sale zemuron muscle relaxant surgical procedure million million represent sale date obs acquisition november december zemuron lose patent exclusivity october lose patent exclusivity global net sale remeron antidepressant million million represent sale date obs acquisition november december global net sale intron injection chronic hepatitis antiviral anticancer indication essentially flat compare decrease percent million compare decrease compare conversion pegintron treat hepatitis japan international net sale subutexsuboxone treatment opiate addiction increase percent million compare sale increase percent million compare increase result primarily benefit foreign exchange global net sale asmanex orally inhale steroid asthma percent million compare primarily market share growth sale increase million compare increase sale pharmaceutical net sale include large number low sale volume prescription pharmaceutical product include billion million net sale ob product respectively product sell limited market outside multiplesource product long protect patent product include treatment respiratory cardiovascular dermatological infectious oncological disease global net sale animal health product increase percent approximately billion compare include global animal health net sale billion relate intervet animal health business obs global net sale benefit solid growth geographic area lead cattle poultry companion animal product line couple positive impact foreign currency exchange rate global net sale increase percent billion compare reflect strong growth core brand geographic specie area lead high sale companion animal product inclusion intervet sale animal health segment sale impact intense competition frequent introduction generic product global net sale consumer health care product include otc foot care sun care product increase percent million compare increase mainly high sale miralax launch february rxtootc switch laxative category year offset low sale otc product otc claritin sale decrease percent million compare result increase competition privatelabel product global net sale increase percent million compare reflect increase sale sun care product scholl product launch miralax addition sale otc claritin increase percent million compare sale growth product form net sale sun care product increase million percent compare primarily success coppertone continuous spray product launch consumer health care market highly competitive heavy advertising consumer frequent competitive product introduction include prescription antihistamine launch otc sale early impact consumer purchase pattern table content cost expense equity income summary cost expense equity income year end december follow incre ase dec rease dollar millions gross margin sell general administrative sga research development acquire inprocess research development iprd expenseincome net special acquisitionrelate charge equity income meaningful percentage substantially sale cholesterol product include scheringplough net sale result sale reflect equity income addition virtual nature joint venture scheringplough incur substantial sell general administrative expense capture equity income include scheringploughs statement consolidated operation result scheringplough gross margin ratio sga expense expense percentage net sale reflect benefit impact joint venture operate result gross margin gross margin percent compare percent gross margin unfavorably impact billion million respectively purchase accounting adjustment include cost sale purchase accounting adjustment result amortization fair value primarily inventory intangible asset acquire obs acquisition gross margin compare benefit realize cost saving approximately million manufacturing streamline nonrecurrence million charge associate aforementioned manufacturing streamlining action favorable product mix sell general administrative selling general administrative expense sga increase percent billion compare increase sga primarily inclusion expense obs impact foreign exchange partially offset productivity transformation program saving sga increase percent billion compare reflect high promotion spend ongoing investment emerge market unfavorable impact foreign exchange research development research development spending increase percent billion compare include upfront payment million mainly relate certain licensing transaction increase spending versus reflect increase spending result obs acquisition high spending clinical trial relate activity investment build great breadth capacity support scheringplough expand global pipeline spending increase percent billion compare increase high cost associate clinical trial build great breadth capacity support scheringplough pipeline change spending reflect timing scheringplough fund internal table content research effort research collaboration partner discover develop steady flow innovative product maximize chance successful development new product scheringplough begin development excellence initiative build talent critical mass create uniform level excellence deliver highpriority program schering plough begin global clinical harmonization program maximize globalize quality clinical trial execution pharmacovigilance regulatory process begin certain aspect global clinical harmonization program implement continue integrate process obs expenseincome net expenseincome net comprise follow year end december dollar million interest cost incur capitalize construction interest expense interest income foreign exchange lossesgain net gain sale divest product realize gain foreign currency option net ineffective portion interest rate swap net total expenseincome net scheringplough million expense net million income net interest expense high issuance new debt connection acquisition ob second half expense net include million million tax gain sale divestiture certain animal health product require regulatory agency europe connection acquisition obs addition scheringplough recognize gain million million tax sale manufacturing site income net include net realize gain foreign currency option million relate obs acquisition increase income net compare reflect high interest income high balance cash equivalent shortterm investment partially offset high interest expense issuance new debt special acquisitionrelate charge manufacture streamline special acquisitionrelate charge special acquisitionrelate charge relate productivity transformation program activity include ongoing integration obs business special acquisitionrelate charge million cost include million employee termination cost remain charge million relate integration activity table content follow table summarize charge cash payment liability relate productivity transformation program include ongoing integration obs december acqu ition relate liability employee employee termination termination exit cost cost cost dollar million accrue liability december chargesa purchase price allocation itemsb cash payment accrue liability december record special acquisitionrelate charge record purchase accounting include acquisitionrelate liability december costs exit certain activity obs special acquisitionrelate charge year end december scheringplough incur million special acquisitionrelate charge comprise million integrationrelate cost obs acquisition million employee termination cost integration activity manufacturing streamline scheringplough implement change manufacture operation puerto rico new jersey streamline global supply chain enhance scheringplough longterm competitiveness change result phaseout closure scheringplough manufacturing operation manati puerto rico additional workforce reduction las piedras puerto rico new jersey special charge special charge relate change scheringploughs manufacturing operation total million charge consist approximately million severance million fix asset impairment cost sale include cost sale approximately million consist million accelerate depreciation million inventory writeoff million charge relate closure scheringplough manufacturing facility manati puerto rico table content follow table summarize activity reflect consolidated financial statement relate change scheringploughs manufacturing operation complete harge include special total cash noncash accrue cost sale charge charge payment charge liability dollar millions accrue liability january severance asset impairment accelerate depreciation inventory writeoff total accrue liability december severance accrue liability december equity income sale merckscheringplough cholesterol joint venture total billion billion billion respectively sale decrease primarily low market share partially offset continued growth international market sale growth compare primarily increase market share company bear cost general sale force commercial overhead marketing joint venture product world canada puerto rico cholesterol agreement provide reimbursement company physician detail set annual basis italy contractual include profit sharing calculation reimburse canada puerto rico equal company agree physician detail multiply contractual fix fee scheringplough report amount equity income amount represent reimbursement specific incremental identifiable cost scheringplough detail cholesterol product market addition amount reflective scheringplough sale effort relate joint venture scheringplough sale force relate cost associate joint venture generally estimate high market scheringplough receive great share profit million annual zetia sale million annual zetia sale merck scheringplough generally share profit equally cost joint venture company contractually share portion manufacturing cost specifically identify promotion cost include directtoconsumer advertising direct identifiable outofpocket promotion agree cost specific service market support market research market expansion specialty sale force physician education program certain specify research development expense generally share equally scheringplough merck allergyasthma agreement provide joint development marketing company oncedaily fixedcombination tablet contain loratadinemontelukast april merckscheringplough joint venture receive notapprovable letter fda propose fix combination loratadinemontelukast second quarter respiratory joint venture terminate accordance agreement action impact cholesterol joint venture result table content termination respiratory joint venture scheringplough receive payment total million scheringplough recognize equity income equity income merckscheringplough joint venture total billion billion billion respectively decrease equity income amount compare reflect sale decline vytorin zetia partially offset sale growth internationally receipt million termination respiratory joint venture increase equity income compare reflect increase sale vytorin zetia compare note scheringplough incur substantial sell general administrative cost reflect equity income instead include overall cost structure scheringplough provision income taxis tax expense million million million respectively tax provision amount include tax benefit million million respectively relate amortization fair value certain asset acquire obs acquisition purchaseaccounte relate item tax provision include benefit relate operating loss scheringplough establish valuation allowance net defer tax asset include benefit operating loss management conclude likely benefit net defer tax asset realize december scheringplough continue maintain valuation allowance net defer tax asset scheringplough expect report net operating loss nol carryforward billion tax return year end december nol carryforward materially reduce examination scheringplough income tax return internal revenue service irs scheringplough implement provision fasb interpretation accounting uncertainty income taxis fin january require fin cumulative effect apply provision interpretation report adjustment scheringplough retain earning balance january scheringplough reduced january retain earning million result adoption fin scheringploughs unrecognized tax benefit result primarily vary application statute regulation interpretation include exposure intercompany term cross border arrangement utilization cash hold foreign subsidiary investment property scheringplough tax matter litigation note legal environmental regulatory matter item financial statement supplementary datum december total unrecognized tax benefit million million respectively include tax liability reduction defer tax asset carry valuation allowance december approximately million million respectively total unrecognized tax benefit recognize affect effective tax rate management believe reasonably possible total unrecognized tax benefit decrease twelvemonth period approximately million primarily attributable decision tax matter currently litigate newark district court decision render possible final resolution scheringplough examination irs appeal possible resolution matter time ultimate resolution scheringplough tax matter payment receipt relate cash dependent number factor outside scheringploughs control scheringplough include interest expense income potential penalty uncertain tax position component income tax expense statement consolidated operation total interest expense relate uncertain tax position year end december million million respectively total accrue interest relate uncertain tax position december million million respectively include accrue liability table content second quarter irs complete examination scheringplough federal income tax return schere plough seek resolution issue raise examination irs administrative appeal process july schering plough payment million irs pertain examination scheringplough tax return open examination irs tax year irs commence examination federal income tax return examination expect complete significant tax jurisdiction state foreign schering plough income tax return open examination period net incomeloss available common shareholder scheringplough net incomeloss available common shareholder billion billion billion respectively net incomeloss available common shareholder include approximately billion billion respectively charge relate purchase accounting obs acquisition net incomeloss available common shareholder include deduction prefer stock dividend million million million respectively relate mandatory convertible preferred share loss impact purchase accounting item obs acquisition increase interest expense result issuance debt second half amount partially offset impact gain currency option period gain divestiture certain animal health product period net incomeloss available common shareholder include special acquisitionrelate charge manufacture streamlining cost approximately million million million respectively note special acquisition relate charge manufacture streamline item financial statement supplementary datum additional information liquidity financial resource discussion cash flow year december dollar million cash flow provide operating activity cash flow investing activity cash flow forprovide financing activity operating activity operating activity provide billion cash compare net cash provide operation billion increase primarily inclusion obs business absence special acquisitionrelate payment associate settlement investigation attorney office district massachusetts involve certain scheringplough sale marketing clinical trial practice program massachusetts investigation net cash provide operating activity billion increase billion compare increase primarily net realize gain million foreign currency option relate obs acquisition high net sale equity income partially offset payment million settlement massachusetts investigation million tax interest connection examination irs scheringploughs federal income tax return overall risk management strategy consideration preliminary financing scenario associate acquisition obs scheringplough purchase eurodenominate currency option derivative aggregate premium approximately million receive proceed table content million termination option result net realize gain million derivative shortterm trading nature hedge specific financing investment transaction accordingly cash impact derivative classified operating cash flow statement consolidated cash flow invest activity net cash investing activity million primarily relate capital expenditure million partially offset proceed divest product million net cash investing activity billion primarily consist billion net cash purchase obs addition source cash investing activity include net reduction shortterm investment billion partially offset million capital expenditure net cash investing activity billion primarily relate net purchase shortterm investment billion previously invest cash equivalent million capital expenditure financing activity net cash financing activity billion compare billion cash provide financing activity use cash financing activity include pay eurodenominate longterm debt euro million debt payment total payment million payment dividend common prefer share million pay commercial paper shortterm debt outstanding million net cash provide financing activity include net proceed issuance common preferred share approximately billion billion respectively net proceed approximately billion issuance longterm debt net cash provide financing activity include million proceed stock option exercise offset payment dividend common prefer share million net cash financing activity billion include payment dividend common prefer share million repayment billion bank debt shortterm commercial paper borrowing discussion cash flow scheringplough expect contribute approximately million retirement plan include approximately million scheringplough retirement plan december scheringplough net debt total debt cash cash equivalent shortterm investment marketable security billion billion respectively cash generate operation available cash shortterm investment available credit facility expect provide scheringplough ability fund cash need intermediate term borrowing credit facility september scheringplough issue billion aggregate principal percent senior unsecured note billion aggregate principal percent senior unsecured note net proceed offer approximately billion interest note payable semiannually effective interest rate percent senior unsecured note percent senior unsecured note incorporate initial discount debt issuance fee percent percent respectively interest rate payable note subject adjustment note generally restrict scheringplough creating assume lien enter sale leaseback transaction aggregate outstanding indebtedness secure lien relate sale leaseback transaction exceed percent consolidate net tangible asset note redeemable scheringplough option time redemption price equal great percent principal note sum present value table content remain schedule payment principal interest discount redemption date semiannual basis rate treasury note comparable remain term plus basis point note basis point note change control trigger event occur certain circumstance define prospectus holder note right require schere plough repurchase note cash payment equal percent aggregate principal note repurchase plus accrue unpaid interest date purchase october scheringplough issue euro million aggregate principal percent senior unsecured euro denominate note euro billion aggregate principal percent senior unsecured eurodenominate note net proceed offer approximately billion interest note payable annually effective interest rate percent senior unsecured eurodenominate note percent senior unsecured eurodenominate note incorporate initial discount debt issuance fee impact interest rate hedge percent percent respectively interest rate payable note subject adjustment note generally restrict scheringplough creating assume lien enter sale leaseback transaction aggregate outstanding indebtedness secure lien relate sale leaseback transaction exceed percent consolidate net tangible asset note redeemable scheringplough option time redemption price specify prospectus change control trigger event occur certain circumstance define prospectus holder note right require scheringplough repurchase note cash payment equal percent aggregate principal note repurchase plus accrue unpaid interest date purchase scheringplough net proceed note fund portion purchase price obs acquisition october scheringplough enter fiveyear senior unsecured eurodenominate term loan facility syndicate bank october scheringplough draw euro billion billion term loan fund portion purchase price obs acquisition term loan float interest rate require scheringplough maintain net debt total capital ratio percent percent net debt equal total debt cash cash equivalent shortterm investment marketable security total capital equal sum total debt total shareholder equity exclude cumulative effect acquire inprocess research development connection acquisition consummate closing term loan term loan generally restrict scheringplough creating assume lien enter sale leaseback transaction aggregate outstanding indebtedness secure lien relate sale leaseback transaction exceed percent consolidate net tangible asset february outstanding balance eurodenominate term loan euro million report dollar amount outstanding debt balance interest expense eurodenominate note euro denominate term loan fluctuate impact foreign currency translation november scheringplough issue billion aggregate principal percent senior unsecured note billion aggregate principal percent senior unsecured note interest rate payable note subject adjustment connection rating downgrade december interest rate payable note increase percent percent interest rate payable note increase percent percent interest rate payable particular series note return percent percent respectively rate adjustment provision permanently cease apply note subsequently rate baa moodys bbb rating assign note moodys downgrade respectively interest rate payable series note increase note borrowing commitment item financial statement supplementary datum additional information august scheringplough enter billion revolving credit agreement syndicate bank terminate billion credit facility mature credit facility float interest rate mature august require scheringplough maintain table content net debt total capital ratio percent percent net debt equal total debt cash cash equivalent shortterm investment marketable security total capital equal sum total debt total shareholder equity exclude cumulative effect acquire inprocess research development connection acquisition consummate closing credit facility credit facility generally restrict scheringplough creating assume lien enter sale leaseback transaction aggregate outstanding indebtedness secure lien relate sale leaseback transaction exceed percent consolidate net tangible asset credit line available general corporate purpose consider primarily support scheringplough commercial paper borrowing borrowing credit facility draw parent company whollyowne international subsidiary accompany parent guarantee facility require compensating balance nominal commitment fee pay december borrowing outstanding facility december shortterm borrowing include credit facility mention total million million respectively outstanding commercial paper december weightedaverage interest rate shortterm borrowing december percent percent respectively scheringplough senior unsecured eurodenominate note eurodenominate term loan designate effective economic hedge net investment foreign operation accordance sfas foreign currency translation sfas foreign currency transaction gain loss eurodenominate debt instrument include foreign currency translation adjustment comprehensive income credit rating scheringplough current unsecured senior credit rating outlook follow longterm senior unsecured credit rating longterm shortterm review status moodys investor service baa stable standard poor stable fitch rating bbb stable february moodys investors service change long term review status scheringplough credit rating negative outlook stable august standard poor fitch rating change long term review status negative watch stable april moodys investor service change long term review status stable negative outlook fitch rating change long term review status stable negative watch march standard poor change long term review status stable negative watch scheringplough pay entire commercial paper borrowing million cash perspective scheringplough remains invest highlyliquid highlyrate security scheringplough remain focused credit market continues closely monitor broad financial economic situation scheringplough believe ability commercial paper issuer schere plough shortterm credit rating moodys andor fitch issue rollover outstanding commercial paper time company high shortterm credit rating total commercial paper capacity available issuer scheringplough typically higherrate company addition schering plough ability issue commercial paper future dependent capital market condition time scheringplough sizable line credit commercial bank cash shortterm investment hold international subsidiary serve alternative source liquidity scheringplough credit rating decline current level impact decline reduce availability commercial paper borrowing increase interest rate portion scheringplough short longterm debt discuss scheringplough believe exist table content cash shortterm investment available credit facility cash generate operation allow scheringplough fund cash need intermediate term mandatory convertible preferred stock august scheringplough issue share percent mandatory convertible preferred stock prefer stock face value billion net proceed scheringplough approximately billion deducting commission discount underwriting expense scheringplough net proceed sale prefer stock fund portion purchase price obs acquisition share prefer stock automatically convert common share scheringplough depend average closing price scheringplough common share trading day period end trading day prior mandatory conversion date august define prospectus prefer shareholder elect convert time prior august minimum conversion ratio common share share prefer stock additionally time prior mandatory conversion date closing price scheringplough common share exceed trading day period consecutive trading day scheringplough elect cause conversion prefer stock outstanding minimum conversion ratio common share share preferred stock prefer stock accrue dividend annual rate percent share outstanding dividend cumulative date issuance extent scheringplough legally permit pay dividend board director declare dividend payable scheringplough pay dividend dividend payment date dividend payment date february august november year year end december share percent mandatory convertible preferred stock issue august preferred stock convert share scheringplough common stock equity issuance treasury share august scheringplough issue common share treasury share share net proceed scheringplough approximately billion deducting commission discount underwriting expense scheringplough net proceed sale common share fund portion purchase price obs acquisition note acquisition item financial statement supplementary datum contractual obligation offbalance sheet arrangement scheringplough contractual obligation report liability consolidated balance sheet require recognize liability certain purchase table content commitment executory contract follow table summarize payment period scheringplough know contractual obligation december ayme nt perio total dollar million shortterm borrowing current portion longterm debt longterm debt obligation interest relate debt obligation operating lease obligation purchase obligation defer compensation plan obligation obligation total purchase obligation include advertising research contract capital expenditure commitment inventory expense item potential milestone payment approximately billion include contractual obligation table contingent achievement research development approximately million regulatory approval approximately million salesbase approximately billion milestone research development regulatory milestone depend future clinical development regulatory agency action occur salesbased milestone contingent generating level sale current future product achieve caption include obligation base undiscounted amount estimate payment certain scheringplough pension plan prefer stock dividend management estimate current portion unrecognize tax benefit contractual obligation regulatory competitive environment scheringplough operate scheringplough subject jurisdiction national state local regulatory agency regulation schere plough subject describe detail item business regulatory compliance complex regulatory standard include good clinical practice good laboratory practice good manufacturing practice vary jurisdiction constantly evolve regulatory compliance costly regulatory compliance impact timing need bring new drug market market drug new indication failure comply regulation result delay approval drug seizure recall drug suspension revocation authority necessary production sale drug fine civil criminal sanction regulatory compliance cost compliance failure material impact scheringplough result operation cash flow financial condition unknown science human health drug benefit risk societal governmental pressure constantly shift demand innovation meet urgent unmet medical need adversity risk pressure impact regulatory environment market scheringplough product regulatory compliance pharmacovigilance regulatory inspection scheringplough subject pharmacovigilance reporting requirement country jurisdiction include member states requirement differ jurisdiction table content jurisdiction include requirement report adverse event occur patient particular drug order alert drug manufacturer governmental agency potential problem february scheringplough begin global clinical harmonization program building clinical excellence trial design execution tracking strengthen scheringplough scientific compliance rigor global basis certain aspect global clinical harmonization program implement significant work continue expect continue year scheringplough intend continue upgrade skill process system clinical practice pharmacovigilance schering plough remain committed accomplish work invest significant resource area like pharmaceutical company scheringplough subject inspection fda emea regulatory authority possible action include demand improvement report system criminal sanction scheringplough andor responsible individual change condition marketing authorization scheringplough product regulatory compliance postmarkete surveillance scheringplough engage clinical trial research country world clinical trial research activity comply stringent regulatory standard subject inspection local country regulatory authority failure comply current good clinical practice applicable law regulation result delay approval clinical trial suspension ongoing clinical trial delay approval marketing authorization criminal sanction scheringplough andor responsible individual financial penalty change condition marketing authorization scheringplough product clinical trial postmarkete surveillance certain market drug competitor industry raise safety concern lead recall withdrawal adverse labeling market product addition situation raise concern prescriber patient relate safety efficacy pharmaceutical product general past year occurrence increase intense medium attention result enhance clinical trial lead concern patient prescriber zetia vytorin discussion item legal proceeding litigation investigation relate merckscheringplough cholesterol joint venture follow wave product withdrawal company significant safety issue health authority fda emea pmda continue increase focus safety assess benefitrisk balance drug fda particular grant new legislative authority include provision focus drug safety pharmacovigilance include ability mandate labeling change require postapproval evaluation study addition health authority appear cautious making decision approvability new product indication rereviewe select product market add uncertainty potential delay regulatory approval process continue significant regulatory legislative scrutiny especially advertising promotion particular directtoconsumer advertising similarly major health authority include fda emea pmda increase collaboration especially regard evaluation safety benefitrisk information medium attention increase current environment health authority regulatory action market safety labeling change regulatory prescribing marketing implication market extent previously see health authority pmda japan publicly acknowledge significant backlog workload resource constraint agency backlog cause long regulatory review time new indication product add uncertainty predict approval timeline market pmda committed correct backlog progress year expect continue foreseeable future table content new presidential administration announce health care reform include regulation pharmaceutical company product priority administration name health human service secretary fda commissioner initiate change impact action budget pressure government nation predict time uncertaintie inherent government regulatory approval process include thing delay approval new product formulation indication affect scheringplough operation effect regulatory approval process operation predict scheringplough achieve significant number important regulatory approval include approval vytorin bridion europe noxafil clarinex clarinex reditab clarinex suboxone new indication temodar nasonex significant approval include asmanex dpi dry powder inhalation pegintron zetia temodar esmeroneslax nasonex ganir japan new indication remicade schering plough number significant regulatory submission file major market await approval include golimumab europe sugammadex saphris asenapine scheringploughs personnel regular open dialogue fda emea regulator review product label material regular basis new information know pricing pressure describe specifically note legal environmental regulatory matter item financial statement supplementary datum pricing sale marketing program arrangement relate business practice scheringplough participant health care industry increase scrutiny federal state regulatory investigative prosecutorial administrative entity entity include department justice attorney office office inspector general department health human service fda ftc state attorney general office health care law certain governmental entity operate include federal state antikickback statute statutory common law false claim law construe broadly court permit government entity exercise significant discretion event governmental entity believe wrongdoing occur institute civil criminal proceeding institute resolve unfavorably subject scheringplough substantial fine penalty injunctive administrative remedy include exclusion government reimbursement program scheringplough predict investigation affect marketing practice sale result material adverse impact scheringplough result operation cash flow financial condition business scheringploughs pharmaceutical product subject increasingly competitive pricing manage care group institution government agency group seek price discount instance party payor use formulary restriction control cost negotiate discount price exchange inclusion formulary change formulary status product impact sale product market scheringplough pharmaceutical manufacturer require provide statutorily define rebate government agency order participate medicaid veterans health care program governmentfunde program medicare prescription drug improvement modernization act contain prescription drug benefit individual eligible medicare result increase use generic increase purchasing power negotiating behalf medicare recipient international market scheringplough operate environment government mandate costcontainment program government place restriction physician prescription level patient reimbursement emphasize great use generic drug enact acrosstheboard price cut method control cost table content scheringplough unable predict final form time future domestic international governmental health care initiative include passage law permit importation pharmaceutical effect operation cash flow reasonably estimate similarly effect operation cash flow future decision government entity manage care group group concern formulary pharmaceutical reimbursement policy reasonably estimate competition market pharmaceutical product competitive scheringplough operation affect technological advance competitor industry consolidation patent grant competitor competitive combination product new product competitor new information clinical trial market product postmarkete surveillance generic competition scheringplough product mature addition patent position increasingly challenge competitor outcome highly uncertain adverse result patent dispute preclude commercialization product negatively affect sale exist product effect operation competitive factor patent dispute predict outlook scheringplough provide numeric guidance follow outlook helpful reader assess future prospect uncertaintie financial credit market generally difficult business condition contribute recently pressure company include pharmaceutical company development economic effect potential healthcare reform federal state level difficult predict scheringplough plan remain flexible manage business face challenge give current uncertainty cholesterol market remain difficult predict longterm performance cholesterol franchise currently scheringplough believe sale vytorin zetia expect low international sale exclude impact foreign exchange continue grow year scheringplough currently expect spending grow mid singledigit range risk set forth item risk factor cause actual result differ materially expectation provide section impact recently issue accounting standard september financial accounting standard board fasb issue statement financial accounting standard sfas fair value measurement standard define fair value establishe framework measure fair value accordance generally accept accounting principle expand disclosure fair value measurement standard codifie definition fair value price receive sell asset pay transfer liability orderly transaction market participant measurement date standard clarifie principle fair value base assumption market participant use price asset liability establish fair value hierarchy prioritize information develop assumption calendaryear company standard effective january note fair value measurement item financial statement supplementary datum nonfinancial item measure nonrecurre basis effective begin january implementation standard material impact scheringplough financial statement base scheringploughs current financial position impact provision standard effective january expect material february fasb issue sfas fair value option financial asset financial liabilitiesincluding amendment fasb statement sfas permit table content entity choose measure financial instrument certain item fair value sfas include amendment sfas account certain investment debt equity security apply entity availableforsale trading security calendaryear company standard effective january scheringplough choose elect fair value option prescribe sfas result implementation standard material impact scheringplough financial statement december fasb issue eitf issue accounting collaborative arrangement effective calendar year company begin january task force clarify manner cost revenue share payment receive partner collaborative arrangement present income statement set forth certain disclosure require partner financial statement impact standard consolidated financial statement expect material december fasb issue sfas revise business combination sfas calendaryear company standard applicable new business combination occur january sfas require acquire entity recognize asset acquire liability assume transaction acquisitiondate fair value limit exception significantly sfas require acquisition cost generally expense incur certain acquire contingent liability record fair value acquire inprocess research development record fair value indefinitelive intangible asset acquisition date standard impact certain unresolved matter relate purchase transaction consummate prior effective date standard impact standard consolidated financial statement expect material standard effect account future business combination december fasb issue sfas noncontrolle interest consolidate financial statement amendment arb effective calendaryear company begin january standard establish new accounting reporting standard noncontrolle interest subsidiary deconsolidation subsidiary impact standard consolidated financial statement expect material march fasb issue sfas disclosure derivative instrument hedging activity amendment fasb statement effective calendaryear company begin january standard enhance require disclosure derivative hedge activity impact standard consolidated financial statement expect material april fasb issue fasb staff position fsp fas determination useful life intangible asset fsp fsp amend factor consider develop renewal extension assumption determine useful life recognize intangible asset sfas goodwill intangible asset sfas fsp effective calendaryear company begin january requirement determine useful life apply prospectively intangible asset acquire effective date disclosure requirement apply prospectively intangible asset recognize subsequent effective date impact standard consolidated financial statement expect material fasb issue sfas hierarchy generally accept accounting principle standard identifie source accounting principle framework select principle preparation financial statement present conformity generally accept accounting principle gaap united states gaap hierarchy sfas effective november implementation standard material impact scheringplough financial statement june fasb issue fsp eitf determine instrument grant sharebased payment transaction participate security fsp address instrument grant sharebased payment transaction participate security prior vest need include earning allocation calculate earning share twoclass method describe table content sfas earning share fsp require company treat unvested sharebased payment award nonforfeitable right dividend dividend equivalent separate class security calculate earning share fsp effective calendar year company begin january impact standard consolidated financial statement expect material october fasb issue fsp determine fair value financial asset market active fsp fsp clarify application sfas inactive market demonstrate fair value financial asset determine market financial asset inactive fsp effective issuance include prior period financial statement issue implementation standard material impact scheringplough financial statement december fasb issue fsp fas fin disclosure public entity enterprise transfer financial asset interest variable interest entity fsp fas fin require enhance disclosure transfer financial asset interest variable interest entity fsp effective interim annual period end december fsp require additional disclosure concern transfer financial asset interest variable interest entity adoption fsp affect scheringploughs disclosure critical accounting policy estimate follow accounting policy estimate consider significant change certain judgment assumption inherent policy affect scheringplough financial statement revenue recognition rebate discount return provision income taxis acquisition impairment goodwill intangible asset property accounting pension postretirement benefit plan account legal regulatory matter revenue recognition scheringploughs pharmaceutical product sell direct purchaser include wholesaler retailer certain health maintenance organization price discount rebate sale pay federal state agency indirect purchaser market participant manage care organization indemnify beneficiary health plan pharmaceutical cost pharmacy benefit manager scheringplough recognize revenue title risk loss pass purchaser reliable estimate follow determined commercial discount rebate arrangements rebate obligation certain federal state governmental program iii sale return normal course business revenue recognition require reasonable assurance collection sale proceed recognize revenue scheringplough estimate record applicable commercial governmental discount rebate sale return expect grant product sell period amount deduct sale period reliable estimate item scheringplough defer recognition revenue estimate record prior period reevaluate process table content revenue recognition new product base specific fact circumstance include estimate acceptance rate establish product similar marketing characteristic absent ability reliable estimate rebate discount return scheringplough defer revenue recognition product discount grant base term arrangement wholesaler manage care organization government purchaser certain market condition rebate estimate base sale contract term historical experience trend analysis project market condition market serve scheringplough evaluate market condition product group product primarily analysis party demand market research datum internally generate information datum information provide purchaser obtain party subject inherent limitation accuracy validity sale return estimate record base historical sale return information analysis recent wholesale purchase information consideration stocking level wholesaler forecast demand amount product exhibit unusual sale return pattern dating competition include expect generic introduction marketing matter specifically investigate analyze formulation return reserve scheringplough agreement major pharmaceutical wholesaler address number commercial issue product return time payment processing chargeback quantity inventory hold wholesaler respect quantity inventory hold wholesaler agreement provide financial disincentive wholesaler acquire quantity product excess necessary meet current patient demand use agreement scheringplough expect avoid situation scheringplough shipment product reflective current demand rebate discount return scheringploughs rebate accrual federal state governmental program include medicaid medicare december million million respectively commercial discount return rebate accrual december million million respectively accrual establish period relate revenue recognize result reduction sale establishment liability include total current liability case return receivable adjustment allowance provide account receivable case governmental rebate programs scheringploughs payment involve interpretation relevant statute regulation interpretation subject challenge change interpretive guidance governmental authority result challenge change affect estimate governmental rebate amount ultimately sufficient satisfy schere plough obligation additional information governmental inquiry focus calculation rebate contain note legal environmental regulatory matter item financial statement supplementary datum addition possible result governmental challenge change interpretive guidance actual rebate materially differ amount accrue table content follow summarize activity account relate accrued rebate sale return discount ear end ear end december december dollar millions accrue rebatesreturnsdiscount begin period obss accrual acquire november provision rebate adjustment prioryear estimate payment provision return purchaseaccounte adjustment adjustment prioryear estimate return provision discount adjustment prioryear estimate discount grant accrue rebatesreturnsdiscount end period year end december purchase accounting adjustment reflect million relate reversal return reserve record purchase accounting obs reversal record reduction goodwill formulate recording accrual management utilize assumption estimate include historical experience wholesaler datum projection market condition estimate lag time sale payment rebate utilization estimate forecast product demand amount discuss critical accounting policy entitle revenue recognition review accrual management perform sensitivity analysis consider differ assumption subject judgment rebate accrual calculation base scheringplough sensitivity analysis reasonably possible change assumption relate rebate accrual favorably unfavorably impact net sale income taxis annual consistent prior year sensitivity analysis exclude potential impact specific matter involve interpretation statute favorable impact net sale income taxis future period provision income taxis scheringplough implement provision fasb interpretation accounting uncertainty income taxis fin january require fin cumulative effect apply provision interpretation report adjustment scheringplough retain earning balance january scheringplough reduced january retain earning million result adoption fin scheringploughs unrecognized tax benefit result primarily vary application statute regulation interpretation include exposure intercompany term cross border arrangement utilization cash hold foreign subsidiary investment property scheringplough tax table content matter litigation note legal environmental regulatory matter item financial statement supplementary datum december total unrecognized tax benefit million million respectively include tax liability reduction defer tax asset carry valuation allowance december approximately million million respectively total unrecognized tax benefit recognize affect effective tax rate management believe reasonably possible total unrecognized tax benefit decrease twelvemonth period approximately million primarily attributable decision tax matter currently litigate newark district court decision render possible final resolution scheringplough examination irs appeal possible resolution matter time ultimate resolution scheringplough tax matter payment receipt relate cash dependent number factor outside scheringploughs control scheringplough include interest expense income potential penalty uncertain tax position component income tax expense statement consolidated operation total interest expense relate uncertain tax position year end december million million respectively total accrue interest relate uncertain tax position december million million respectively include accrue liability acquisition impairment goodwill intangible asset property scheringplough account acquire business purchase method accounting require asset acquire liability assume record date acquisition respective fair value consolidate financial statement result operation reflect acquire business completion acquisition cost acquire business include transaction cost allocate underlie net asset acquire business base respective fair value excess purchase price estimate fair value net asset acquire record goodwill amount allocate acquire inprocess research development expense date acquisition intangible asset amortize straightline basis expect life asset judgment determine estimate fair value assign class asset acquire liability assume asset live materially impact result operation useful life determine base expect future period benefit asset consider characteristic asset include project cash flow recoverability goodwill measure reporting unit level base twostep approach carry report unit compare fair value estimate future net discount cash flow expect generate reporting unit extent carry value report unit exceed fair value report unit second step perform reporting unit asset liability fair value extent report unit carry value goodwill exceed imply fair value goodwill impairment exist recognize intangible asset represent capitalize cost purchase goodwill patent license form intellectual property total billion billion december december respectively intangible asset goodwill increase significantly acquisition obs annual amortization expense year estimate approximately million year base intangible asset record december value asset subject continue scientific medical marketplace uncertainty example market pharmaceutical product withdraw market safety reason marketing product occur pronounce warning amount capitalize product need reduce impairment event give rise impairment inherent risk pharmaceutical industry predict management regularly review intangible asset possible impairment certain scheringplough manufacturing site operate capacity overall cost operate manufacture site significantly increase past year compliance activity scheringplough manufacturing cost base relatively fix action management table content significantly reduce scheringploughs manufacturing infrastructure involve complex issue result shift product manufacturing plant year construction regulatory requirement include revalidation registration requirement management continue review carry value certain manufacturing asset indication impairment future event decision lead additional asset impairment andor relate cost account pension postretirement benefit plan pension postretirement benefit plan information financial reporting purpose calculate actuarial assumption scheringplough assess pension postretirement benefit plan assumption regular basis evaluate assumption scheringplough consider factor include evaluation discount rate expect rate return plan asset healthcare cost trend rate retirement age assumption scheringplough historical assumption compare actual result analysis current market condition asset allocation note retirement plan postretirement benefit item financial statement supplementary datum additional information discount rate pension postretirement benefit plan calculation evaluate annually modify reflect prevail market rate measurement date highquality fix income debt instrument portfolio provide future cash flow need pay benefit include benefit obligation come country debt instrument thinly trade estimate base available market rate actuarial assumption base management good estimate judgment assumption hold constant increase basis point discount rate estimate favorable impact million net pension postretirement benefit cost increase basis point expect rate return assumption estimate favorable impact million net pension postretirement benefit cost assumption hold constant decrease basis point discount rate estimate unfavorable impact million net pension postretirement benefit cost decrease basis point expect rate return assumption estimate unfavorable impact million net pension postretirement benefit cost sensitivity base estimate net pension postretirement benefit cost include annual impact obss plan expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay develop expect rate return scheringplough determine expect return major asset class principally equities fix income real estate return expectation asset class base assumption economic growth inflation support longterm historical datum scheringplough actual experience return plan asset expect portfolio performance reflect active management appropriate condition worldwide debt equity market deteriorate significantly condition negative effect fair value plan asset unrecognize net loss amount reflect experience differential primarily relate difference expect actual return plan asset effect change actuarial assumption expect return base primarily calculate marketrelated value asset methodology asset gainslosse result actual return differ scheringplough expect return majority asset realize marketrelated value asset ratably fiveyear period total unrecognized net loss amount excess certain threshold amortize net pension postretirement benefit cost average remain service life employee scheringplough practice fund qualified pension plan sufficient amount meet minimum requirement set forth applicable law scheringplough expect contribute approximately million retirement plan include approximately million scheringplough retirement plan table content target investment portfolio scheringplough retirement plan allocate percent equity percent fix income investment percent real estate target investment portfolio scheringplough postretirement benefit plan allocate percent equity percent fix income investment portfolio equity weighting consistent longterm nature plan benefit obligation nonus pension plan target investment portfolio vary base duration pension liability local governmental rule regulation substantially investment equities fix income value base quote public market value investment real estate value base periodic appraisal account legal regulatory matter management judgment estimate require account legal regulatory matter ongoing basis include insurance coverage scheringplough review status claim investigation legal proceeding ongoing basis time time scheringplough settle resolve matter term condition management believe good interest scheringplough resolution claim investigation legal proceeding individually aggregate material adverse effect scheringplough result operation cash flow financial condition market risk disclosure scheringplough expose market risk primarily change foreign currency exchange rate less extent interest rate equity price follow describe nature risk foreign currency exchange risk scheringplough subsidiary country sale outside account approximately percent global sale virtually sale denominate currency local country scheringplough report sale profit cash flow expose change exchange rate date management deem cost effective engage formulabase program hedge profit cash flow international operation derivative financial instrument scheringplough international subsidiary purchase significant quantity inventory payable dollar manage level inventory relate payable rate inventory turnover provide level protection adverse change exchange rate risk adverse exchange rate change mitigate fact scheringplough international operation widespread net asset scheringplough international subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate record foreign currency translation account separate component shareholder equity remain international subsidiary nonmonetary asset liability translate historical rate monetary asset liability translate current rate dollar effect rate change include statement consolidated operation occasion scheringplough derivative hedge specific foreign currency exposure overall risk management strategy consideration preliminary financing scenario associate acquisition obs scheringplough purchase eurodenominate currency option mitigate exposure event significant strengthening euro compare dollar scheringplough purchase option aggregate premium approximately million receive proceed million termination option result net realize gain million derivative qualify hedge accounting accordance sfas accounting derivative instrument hedge activity amend sfas accordingly gain derivative recognize statement consolidated operation december open foreign currency option contract table content scheringplough senior unsecured eurodenominate note eurodenominate term loan designate effective economic hedge net investment foreign operation accordance sfas foreign currency transaction gain loss eurodenominate debt instrument include foreign currency translation adjustment comprehensive income interest rate equity price risk financial asset expose change interest rate andor equity price primarily cash equivalent shortterm investment debt equity security hold nonqualified trust employee benefit asset total billion december cash equivalent shortterm investment percent decrease interest rate decrease interest income approximately million security hold qualified nonqualified trust longterm nature liability trust asset fund scheringplough exposure market risk deem low financial obligation expose variability interest rate primarily shortterm borrowing longterm floatingrate euro denominate term loan scheringplough longterm fix rate debt outstanding percent decrease interest rate increase fair value debt december approximately million scheringplough execute series interest rate swap anticipation financing acquisition obs objective swap hedge interest rate payment future issuance debt swap designate cash flow hedge future interest payment accordance sfas effective portion gain loss hedge report comprehensive income ineffective portion report operation connection eurodenominate debt issuance describe note borrowing commitment item financial statement supplementary datum portion swap deem ineffective scheringplough recognize million loss statement consolidated operation effective portion swap million record comprehensive income recognize interest expense life relate debt december open interest rate swap disclosure notice cautionary statement private security litigation reform act management discussion analysis financial condition result operation section report write report oral statement time time scheringplough contain forwardlooke statement mean private security litigation reform act forwardlooke statement relate strictly historical current fact base current expectation forecast future event identify forwardlooke statement use word anticipate believe estimate expect forecast project intend plan potential similar word term particular forwardlooke statement include statement relate future action ability access capital market pende acquisition prospective product product approval time condition regulatory approval patent intellectual property protection future performance effectiveness market product pipeline drug trend performance include trend cholesterol market sale effort research development program anticipate spending estimate rebate discount return expense program reduce expense outcome contingency litigation investigation growth strategy expect synergies financial result forwardlooke statement publication turn wrong guarantee schere plough financial operational performance performance scheringplough stock scheringplough assume obligation update forwardlooke statement factor cause actual result differ scheringplough forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include table content know possible predict identify factor scheringplough refer item risk factor report scheringplough incorporate reference identification important factor respect risk uncertainty item quantitative qualitative disclosure market risk market risk disclosure set forth item management discussion analysis financial condition result operation item financial statement supplementary datum index financial statement statement consolidated operation year end december statement consolidated cash flow year end december consolidated balance sheet december statement consolidated shareholder equity year end december note consolidated financial statement report independent register public accounting firm table content scheringplough corporation subsidiary statement consolidated operation amount million share figure year de december net sale cost sale sell general administrative research development acquire inprocess research development expenseincome net special acquisitionrelate charge equity income incomeloss income taxis cumulative effect change accounting principle income tax expense net incomeloss cumulative effect change accounting principle cumulative effect change accounting principle net tax net incomeloss prefer stock dividend net incomeloss available common shareholder dilute earningsloss common share earningsloss available common shareholder cumulative effect change accounting principle cumulative effect change accounting principle net tax dilute earningsloss common share basic earningsloss common share earningsloss available common shareholder cumulative effect change accounting principle cumulative effect change accounting principle basic earningsloss common share dividend common share accompany note integral consolidated financial statement table content scheringplough corporation subsidiary statement consolidated cash flow amount million year ded december operating activity net incomeloss cumulative effect change accounting principle net tax net incomeloss cumulative effect change accounting principle net tax adjustment reconcile net incomeloss cumulative effect change accounting principle net tax net cash provide operating activity depreciation amortization accrue sharebase compensation special acquisitionrelate charge payment gain sale divest product purchase derivative currency option change fair value currency option proceed derivative instrument acquire inprocess research development payment tax authority change asset liability account receivable inventory prepaid expense asset account payable liability income taxis payable foreign currency transaction exchange loss net net cash provide operating activity invest activity capital expenditure dispositions property equipment proceed divest product net acquisition net cash acquire purchase shortterm investment maturitie shortterm investment net net cash investing activity financing activity cash dividend pay common shareholder cash dividend pay prefer shareholder proceed prefer stock issuance net proceed common stock issuance net paymentsissuance longterm debt net issuance cost payment shortterm borrowing stock option exercise net net cash forprovided financing activity effect exchange rate cash cash equivalent net increasedecrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year supplemental disclosure cash pay interest net amount capitalize cash pay income taxis note accompany note integral consolidated financial statement table content scheringplough corporation subsidiary consolidate balance sheet amount million share figure mber assets current asset cash cash equivalent shortterm investment account receivable allowance inventory defer income taxis prepaid expense current asset total current asset property cost land building improvement equipment construction progress total accumulate depreciation property net goodwill intangible asset net asset total asset liability shareholder equity current liability account payable shortterm borrowing current portion longterm debt income taxis accrue compensation accrue liability total current liability longterm liability longterm debt net current portion defer income taxis longterm liability total longterm liability commitment contingent liability note shareholder equity mandatory convertible preferred share par value share face value issue december december common share authorize share par value issue december december paidin capital retain earning accumulate comprehensive loss total treasury share cost total shareholder equity total liability shareholder equity accompany note integral consolidated financial statement table content scheringplough corporation subsidiary statement consolidated shareholder equity amount million ccumulate mandatory mandatory total convertible convertible compre share prefer preferred common paidin retain treasury hensive holder share share share capital earning share loss equity balance january comprehensive income net income foreign currency translation minimum pension liability net tax sfas unrealize gain investment available sale net tax total comprehensive income cash dividend common share dividend preferred share accrue dividend common share adjustment pension postretirement liability adoption sfas net tax stock incentive plan balance december adoption fin net loss foreign currency translation pension otherpost retirement liability net tax derivative interest rate instrument unrealize gain investment available sale net tax total comprehensive loss issuance preferred stock issuance common stock conversion prefer stock sfas measurement date provision net tax cash dividend common share dividend preferred share accrue dividend common share stock incentive plan balance december net income foreign currency translation pension postretirement liability net tax derivative interest rate instrument unrealize loss investment available sale total comprehensive income dividend common share dividend preferred share stock incentive plan balance december accompanying note integral consolidated financial statement table content note consolidated financial statement summary significant accounting policy overview scheringplough innovationdriven sciencecentere global health care company biopharmaceutical research collaboration partner scheringplough create therapy help save improve life world scheringplough apply research development platform prescription pharmaceutical consumer health care product animal health product november scheringplough acquire organon bioscience obs company discover develop manufacture human prescription animal health product note acquisition additional information principle consolidation consolidated financial statement include scheringplough corporation subsidiary scheringplough intercompany balance transaction eliminate account obs include scheringplough result date acquisition november note acquisition additional information use estimate preparation financial statement conformity accounting principle generally accept require management estimate assumption affect report amount asset liability disclosure contingent asset liability date financial statement report amount revenue expense report period ongoing basis scheringplough evaluate estimate base historical experience assumption believe reasonable circumstance actual result differ estimate equity method accounting scheringplough account share activity merckscheringplough joint venture joint venture merck inc merck equity method accounting scheringplough significant influence joint venture operate financial policy accordingly scheringplough net sale include sale joint venture scheringplough share earning joint venture include equity income determine consolidated net incomeloss equity income joint venture include prescription pharmaceutical segment revenue sale vytorin zetia recognize joint venture title risk loss pass customer reasonable assurance collection sale proceed equity income joint venture exclude profit arise transaction scheringplough joint venture time underlying profit realize joint venture transaction party scheringplough merck note equity income additional information joint venture cash cash equivalent cash cash equivalent include operate cash highly liquid investment original maturity month include highly rate money market account shortterm investment shortterm investment carry fair value classify availableforsale investment consist certificate deposit commercial paper maturity year table content note consolidated financial statement continue inventory inventory value low cost market cost determine lastin firstout lifo method substantial portion inventory locate cost inventory determine firstin firstout method fifo depreciation property equipment depreciation provide estimate useful life property generally use straightline method useful life property acquisition generally follow asset category ear building build improvement equipment scheringplough review carry value property equipment indication impairment accordance statement financial accounting standard sfas accounting impairment disposal longlive asset depreciation expense million million million depreciation expense include accelerate depreciation relate manufacturing streamline million foreign currency translation net asset scheringplough international subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate record foreign currency translation account include comprehensive incomeloss reflect separate component shareholder equity remain international subsidiary nonmonetary asset liability translate historical rate monetary asset liability translate current rate dollar effect rate change include statement consolidated operation exchange gain loss arise translate intercompany balance longterm investment nature record foreign currency translation account transactional exchange gain loss include expenseincome net revenue recognition scheringploughs pharmaceutical product sell direct purchaser include wholesaler retailer certain health maintenance organization price discount rebate sale pay federal state agency indirect purchaser market participant manage care organization indemnify beneficiary health plan pharmaceutical cost pharmacy benefit manager scheringplough recognize revenue title risk loss pass purchaser reliable estimate follow determined commercial discount rebate arrangements rebate obligation certain federal state governmental program iii sale return normal course business revenue recognition require reasonable assurance collection sale process table content note consolidated financial statement continue recognize revenue scheringplough estimate record applicable commercial governmental discount rebate sale return expect grant product sell period amount deduct sale period reliable estimate item scheringplough defer recognition revenue estimate record prior period reevaluate process earning common share dilute earningsloss common share compute divide net incomeloss available common shareholder plus preferred stock dividend dilutive effect mandatory convertible preferred stock sum weight average number common share outstanding plus dilutive effect share issuable defer stock unit exercise stock option dilutive effect share issuable conversion scheringplough mandatory convertible preferred stock basic earningsloss common share compute divide net incomeloss available common shareholder weight average number common share outstanding goodwill intangible asset financial accounting standard board fasb sfas goodwill intangible asset require intangible asset acquire individually group asset initially recognize measure base fair value intangible finite life amortize useful life intangible indefinite life include goodwill amortize company assess recoverability carrying value goodwill intangible asset indefinite useful life annually event change circumstance indicate carry asset fully recoverable recoverability goodwill measure reporting unit level base twostep approach carry report unit compare fair value estimate future net discount cash flow expect generate reporting unit extent carry value report unit exceed fair value report unit second step perform reporting unit asset liability fair value extent report unit carry value goodwill exceed imply fair value goodwill impairment exist recognize recoverability intangible asset indefinite useful life measure comparison carry intangible asset fair value respective intangible asset excess carrying value intangible asset fair value intangible asset recognize impairment loss scheringplough conduct annual impairment testing goodwill october year base impairment test perform impairment goodwill scheringplough goodwill intangible asset balance increase significantly acquisition obs note acquisition note goodwill intangible asset additional information asset include asset capitalize software million million december respectively amortization expense million million million respectively asset december include million restrict cash primarily letter credit relate certain international tax matter table content note consolidated financial statement continue income taxis scheringplough implement provision fasb interpretation accounting uncertainty income taxis fin january fin order recognize uncertain tax benefit taxpayer likely sustain position measurement benefit calculate large percent likely realize resolution position scheringplough include interest expense income potential penalty uncertain tax position component income tax expense statement consolidated operation defer income taxis recognize future tax effect temporary difference financial income tax reporting basis scheringplough asset liability base enact tax law rate accounting sharebase compensation prior january scheringplough account stockbase compensation arrangement intrinsic value method sharebase employee compensation cost reflect statement consolidated operation scheringplough defer stock unit performance plan stock option grant plan exercise price equal market value underlie common stock date grant effective january scheringplough account sharebase compensation accordance sfas revise sharebased payment sfas note sharebase compensation additional information shipping handling expense shipping expense classify sell general administrative expense consolidate statement operation impact recently issue accounting pronouncement september fasb issue sfas fair value measurement standard define fair value establishe framework measure fair value accordance generally accept accounting principle expand disclosure fair value measurement standard codifie definition fair value price receive sell asset pay transfer liability orderly transaction market participant measurement date standard clarifie principle fair value base assumption market participant use price asset liability establish fair value hierarchy prioritize information develop assumption calendaryear company standard effective january note fair value measurement nonfinancial item measure nonrecurre basis effective begin january implementation standard material impact scheringplough financial statement base scheringploughs current financial position impact provision standard effective january expect material february fasb issue sfas fair value option financial asset financial liabilitiesincluding amendment fasb statement sfas permit entity choose measure financial instrument certain item fair value sfas include amendment sfas account certain investment debt equity security apply entity availableforsale trading security calendaryear company standard effective january scheringplough choose elect fair value option prescribe sfas result implementation standard material impact scheringplough financial statement table content note consolidated financial statement continue december fasb issue eitf issue accounting collaborative arrangement effective calendar year company begin january task force clarify manner cost revenue share payment receive partner collaborative arrangement present income statement set forth certain disclosure require partner financial statement impact standard consolidated financial statement expect material december fasb issue sfas revise business combination sfas calendaryear company standard applicable new business combination occur january sfas require acquire entity recognize asset acquire liability assume transaction acquisitiondate fair value limit exception significantly sfas require acquisition cost generally expense incur certain acquire contingent liability record fair value acquire inprocess research development record fair value indefinitelive intangible asset acquisition date standard impact certain unresolved matter relate purchase transaction consummate prior effective date standard impact standard consolidated financial statement expect material standard effect account future business combination december fasb issue sfas noncontrolle interest consolidate financial statement amendment arb effective calendaryear company begin january standard establish new accounting reporting standard noncontrolle interest subsidiary deconsolidation subsidiary impact standard consolidated financial statement expect material march fasb issue sfas disclosure derivative instrument hedging activity amendment fasb statement effective calendaryear company begin january standard enhance require disclosure derivative hedge activity impact standard consolidated financial statement expect material april fasb issue fasb staff position fsp fas determination useful life intangible asset fsp fsp amend factor consider develop renewal extension assumption determine useful life recognize intangible asset sfas fsp effective calendaryear company begin january requirement determine useful life apply prospectively intangible asset acquire effective date disclosure requirement apply prospectively intangible asset recognize subsequent effective date impact standard consolidated financial statement expect material fasb issue sfas hierarchy generally accept accounting principle standard identifie source accounting principle framework select principle preparation financial statement present conformity generally accept accounting principle gaap united states gaap hierarchy sfas effective november implementation standard material impact scheringplough consolidated financial statement june fasb issue fsp eitf determine instrument grant sharebased payment transaction participate security fsp address instrument grant sharebased payment transaction participate security prior vest need include earning allocation calculate earning share twoclass method describe sfas earning share fsp require company treat unvested sharebased payment award non forfeitable right dividend dividend equivalent separate class security calculate earning share fsp effective calendaryear company begin january impact standard consolidated financial statement expect material table content note consolidated financial statement continue october fasb issue fsp determine fair value financial asset market active fsp fsp clarify application sfas inactive market demonstrate fair value financial asset determine market financial asset inactive fsp effective issuance include prior period financial statement issue implementation standard material impact scheringplough consolidated financial statement december fasb issue fsp fas fin disclosure public entity enterprise transfer financial asset interest variable interest entity fsp fas fin require enhance disclosure transfer financial asset interest variable interest entity fsp effective interim annual period end december fsp require additional disclosure concern transfer financial asset interest variable interest entity adoption fsp affect scheringploughs disclosure acquisition scheringplough acquire obs purchase price approximately euro billion cash approximately billion include legal professional fee november acquisition date acquisition add diversification market product include new therapeutic area women health central nervous system significant strength animal health product pipeline purchase method accounting account transaction accordance sfas business combination operating result obs include scheringplough consolidated financial statement period subsequent acquisition date follow table provide unaudited pro forma financial information year end december acquisition occur begin period present dollar million share datum unaudite net sale net loss cumulative effect change accounting principle net loss available common shareholder dilute loss common share basic loss common share unaudite pro forma financial information period present include amortization stepup inventory billion acquire inprocess research development charge billion nonrecurring charge directly attributable accounting acquisition unaudite pro forma financial information include effect purchase accounting adjustment additional amortization expense acquire identifiable intangible asset depreciation stepup property effect give unaudited pro forma financial information synergistic benefit realize cost relate integration obs unaudite pro forma financial information consider indicative actual result achieve acquisition consummate date indicate purport indicate result operation future date future period preliminary allocation purchase price obs acquisition date final allocation purchase price result net decrease goodwill million compare preliminary allocation acquisition date adjustment preliminary purchase price allocation primarily relate update valuation identifiable intangible asset property inventory table content note consolidated financial statement continue update acquire liability defer taxis final allocation purchase price obs follow ollar million cash current asset exclude inventory inventory property identifiable intangible asset goodwill othernon current asset acquire inprocess research development iprd total asset acquire acquisition relate liability current liability defer tax liability othernon current liability total liability assume net asset acquire final purchase price allocation identifiable intangible asset follow eightedaverage amortization period year dollar million patent women health contraception women health fertility women health central nervous system human prescription pharmaceutical total patent trademark animal health prescription pharmaceutical total trademark total intangible asset acquire weightedaverage life total acquire intangible asset approximately year intangible asset significant residual value acquire intangible asset determine indefinite life billion goodwill assign prescription pharmaceutical segment million assign animal health segment goodwill deductible income tax purpose table content note consolidated financial statement continue billion assign acquire iprd charge operation fourth quarter charge associate research project animal health research project womens health central nervous system anesthesia therapeutic area human health determine discount cash flow projection identify research project technological feasibility establish alternative future use discount rate range percent percent project launch date follow food drug administration fda regulatory approval year time scheringplough expect project begin generate cash flow cost complete research project depend project bring final stage development ultimately submit fda regulatory agency approval december estimate cost complete project near final stage development excess million research development project consider valuation subject normal risk uncertainty associate demonstrate safety efficacy require obtain fda regulatory approval include acquisition relate liability cost exit certain activity obs conjunction obs acquisition scheringplough agree div certain asset regulatory review europe note expenseincome net special acquisition relate charge manufacture streamline special acquisitionrelate charge special acquisitionrelate charge relate productivity transformation program ptp activity include ongoing integration obs business note obs integration productivity transformation program additional information special acquisitionrelate charge million cost include million employee termination cost remain charge relate integration activity special acquisitionrelate charge year end december scheringplough incur million special acquisitionrelate charge comprise million integrationrelate cost obs acquisition million employee termination cost integration activity manufacturing streamline scheringplough implement change manufacture operation puerto rico new jersey streamline global supply chain enhance scheringplough longterm competitiveness change result phaseout closure scheringplough manufacturing operation manati puerto rico additional workforce reduction las piedras puerto rico new jersey special charge special charge relate change scheringploughs manufacturing operation total million charge consist approximately million severance million fix asset impairment cost sale include cost sale approximately million consist million accelerate depreciation million inventory writeoff million charge relate closure scheringplough manufacturing facility manati puerto rico table content note consolidated financial statement continue follow table summarize activity reflect consolidated financial statement relate change scheringploughs manufacturing operation complete charge include special total cash noncash accrue cost sale charge charge payment charge liability dollar millions accrue liability january severance asset impairment accelerate depreciation inventory writeoff total accrue liability december severance accrue liability december obs integration productivity transformation program purchase price allocation obs acquisition acquisition date scheringplough record acquisitionrelate liability million relate involuntary termination benefit april scheringplough announce major new program productivity transformation program ptp include ongoing integration obs design reduce avoid cost increase productivity target saving envision program include result previously announce obs integration synergy follow table summarize charge cash payment liability relate productivity transformation program include ongoing integration obs december acqu ition relate liability employee employee termination termination exit cost cost cost dollar million accrue liability december chargesa purchase price allocation itemsb cash payment accrue liability december record special acquisitionrelate charge record purchase accounting include acquisitionrelate liability december costs exit certain activity obs equity income scheringplough merck enter separate set agreement jointly develop market certain product include cholesterollowere drug allergyasthma table content note consolidated financial statement continue drug december cholesterol agreement expand include country world japan general company agree collaborative activity agreement operate virtual joint venture maximum degree possible rely respective infrastructure company agreement generally provide equal sharing development cost copromotion approve product company cholesterol agreement provide scheringplough merck jointly develop commercialize ezetimibe cholesterol management field oncedaily monotherapy manage zetia asia ezetrol europe coadministration approve statin drug iii fixedcombination tablet ezetimibe simvastatin zocor merck cholesterolmodifye medicine combination medication ezetimibesimvastatin manage vytorin inegy international country zetiaezetrol ezetimibe vytorininegy combination ezetimibesimvastatin approve use launch international market scheringplough utilize equity method accounting recording share activity merckscheringplough cholesterol joint venture scheringplough net sale include sale joint venture cholesterol joint venture agreement provide share operating income generate joint venture base percentage vary product sale level country market scheringplough receive great share profit million annual zetia sale million annual zetia sale merck scheringplough generally share profit equally scheringplough allocation joint venture income increase milestone recognize company share joint venture income operation subject reduction company fail perform specify minimum number physician detail particular country company agree annually minimum number physician detail country company bear cost general sale force commercial overhead marketing joint venture product world canada puerto rico cholesterol agreement provide reimbursement company physician detail set annual basis italy contractual include profit sharing calculation reimburse canada puerto rico equal company agree physician detail multiply contractual fix fee scheringplough report amount equity income cholesterol joint venture amount represent reimbursement specific incremental identifiable cost schere plough detail cholesterol product market addition amount reflective scheringplough sale effort relate joint venture scheringplough sale force relate cost associate joint venture generally estimate high cost joint venture company contractually share portion manufacturing cost specifically identify promotion cost include directtoconsumer advertising direct identifiable outofpocket promotion agree cost specific service market support market research market expansion specialty sale force physician education program certain specify research development expense generally share equally scheringplough merck allergyasthma agreement provide joint development marketing company oncedaily fixedcombination tablet contain loratadinemontelukast april merckscheringplough joint venture receive notapprovable letter fda propose fix combination loratadinemontelukast second quarter respiratory joint venture terminate accordance agreement action impact cholesterol joint venture result table content note consolidated financial statement continue termination respiratory joint venture schering plough receive payment total million scheringplough recognize equity income follow information provide summary component scheringploughs equity income cholesterol joint venture year end december dollar millions scheringploughs share net income include milestone million contractual amount physician detail elimination intercompany profit net total equity income merckscheringplough joint venture december scheringplough net receivables include undistributed income merckscheringplough joint venture million million respectively equity income joint venture exclude profit arise transaction scheringplough joint venture time underlying profit realize joint venture transaction party scheringplough merck virtual nature cholesterol joint venture scheringplough incur substantial cost sell general administrative cost reflect equity income bear overall cost structure scheringplough cost report respective line item statement consolidated operation separately identifiable cholesterol agreement provide jointly own facility product result joint venture manufacture facility own scheringplough merck scheringplough merck develop singletablet combination ezetimibe atorvastatin treatment elevate cholesterol level note legal environmental regulatory matter litigation investigation relate merckscheringplough cholesterol joint venture sharebase compensation prior january scheringplough account stock compensation arrangement intrinsic value method follow recognition measurement principle apb opinion accounting stock issue employee relate interpretation prior stockbase employee compensation cost reflect statement consolidated operation scheringplough defer stock unit stock option grant plan exercise price equal market value underlie common stock date grant scheringplough adopt sfas effective january sfas require company recognize compensation expense equal fair value sharebase payment grant employee scheringplough elect modify prospective transition method adjustment prior period require result adopt sfas method provision sfas apply award grant date adoption unrecognized expense awards unveste date adoption base grant date fair value sfas amend sfas statement cash flow require excess tax benefit reflect operate cash flow reflect finance cash flow grant issue retirementeligible employee prior adoption sfas scheringplough recognize compensation cost state vest period stock option defer stock unit acceleration unrecognize compensation cost retirement employee adoption table content note consolidated financial statement continue sfas scheringplough recognize compensation cost sharebase grant january service period early year employee retirementeligible year grant employee retirement eligibility date year grant iii service period award november fasb issue fasb staff position fas transition election relate accounting tax effect sharebase payment award scheringplough elect adopt transition method provide fasb staff position purpose calculate pool excess tax benefit available absorb tax deficiency recognize subsequent adoption sfas stock incentive plan plan approve scheringplough shareholder term plan million scheringplough authorize common share grant stock option award deferred stock unit officer certain employee scheringplough december scheringplough intend utilize unissued authorized share satisfy stock option exercise issuance defer stock unit expense relate sharebased compensation classify line item associate employee function scheringplough grant performancebase deferred stock unit stock incentive plan provide certain senior manager opportunity earn share scheringplough common stock unit earn specific preestablishe level performance service achieve applicable threeyear performance period implementation sfas quarter scheringplough recognize benefit income million cumulative effect change accounting principle relate longterm compensation plan require account liability plan sfas tax benefit recognize related stockbased compensation relate cash flow impact material scheringplough net operating loss position stock option stock option grant employee exercise price equal fair market value scheringplough stock date grant stock option plan generally vest year term seven year certain option grant previous plan vest long period range year term year compensation cost stock option recognize requisite service period separately vest portion stock option award expense recognize net estimate forfeiture vest period option accelerated method expense recognize approximately million million million respectively weightedaverage assumption blackschole optionprice model follow dividend yield volatility riskfree interest rate expect term option year dividend yield base historical dividend yield expect volatility base historical volatility scheringplough common stock expect differ materially future table content note consolidated financial statement continue volatility riskfree interest rate base treasury yield curve effect time grant period correspond expect life option expect term option represents weight average period time option grant expect outstanding give consideration vest schedule scheringplough utilize simplify method calculate expect term stock option allow staff accounting bulletin sab amend sab historical experience expect reasonable basis estimate expect term change business cash receive exercise stock option million million million respectively summarize information stock option outstanding exercisable december follow tstande exerc able weighted weight weight number average average number average remain exercise exercise exercise price range option term year price option price thousand thousand weightedaverage fair value stock option grant respectively intrinsic value stock option exercise million million million respectively total fair value option vest million million million respectively december total remain unrecognized compensation cost relate nonveste stock option amount million amortize weightedaverage remain requisite service period year follow table summarize stock option activity december change year end current prior plan eighte number average exercise option price thousand outstanding january grant exercise cancel expire outstanding december exercisable december aggregate intrinsic value stock option outstanding december million aggregate intrinsic value stock option currently exercisable december million intrinsic value stock option calculate base exercise price underlie award quote price scheringplough common stock reporting date table content note consolidated financial statement continue follow table summarize nonveste stock option activity december change year end current prior plan eighte average number fair option value thousand nonveste january grant vested forfeited nonveste december defer stock unit fair value defer stock unit determine base number share grant quote price scheringplough common stock date grant defer stock unit generally vest end year provide employee remain service scheringplough expense recognize straightline basis vest period defer stock unit payable equivalent number common share expense recognize million million million respectively summarize information defer stock unit outstanding december follow tstande weight number average weight defer remain average defer stock unit price range stock unit term year fair value thousand weightedaverage fair value defer stock unit grant respectively total fair value defer stock unit vest million million million respectively december total remain unrecognized compensation cost relate deferred stock unit amount million amortize weightedaverage remain requisite service period year table content note consolidated financial statement continue follow table summarize defer stock unit activity december change year end current prior plan number nonveste weight defer average stock unit fair value thousand nonveste january grant vested forfeited nonveste december performancebase deferred stock unit distribution performancebase defer stock unit contingent scheringplough meeting performance andor market condition half performancebase stock unit grant performance condition fair value unit base close stock price date grant half grant market condition fair value unit determine lattice valuation model expect volatility assumption assumption appropriate determine fair value compensation expense performancebase stock unit exclude dividend equivalent base fair value award expect vest base performance measure recognize performance period total compensation expense recognize year end million million respectively weight average grantdate fair value performancebase deferred stock unit grant respectively represent approximately underlie share respectively december unit vest december unrecognized compensation cost relate deferred stock unit million amortize remain weight average requisite service period year remain unrecognized compensation cost performance base deferred stock unit vary report period base change expect achievement performance measure follow table summarize performancebase deferred stock unit activity december change year end number nonveste performancebase weight defer stock average unit fair value thousand nonveste january grant vested forfeited nonveste december liability plan scheringplough compensation plan performance vest period end december plan classify liability plan sfas ultimate cash payout plan base scheringploughs stock performance compare stock table content note consolidated financial statement continue performance peer group adoption sfas january scheringplough recognize cumulative income effect change accounting principle million order recognize liability plan fair value service period income expense amount relate liability plan base change fair value report date fair value plan prior end service period estimate lattice valuation model expect volatility assumption assumption appropriate determine fair value liability plan service period conclude december value plan fix second liability plan service period conclude december income expense recognize liability plan statement consolidated operation exclusive impact cumulative effect change accounting principle income million expense million million respectively december remain unrecognized compensation cost relate liability plan expenseincome net component expenseincome net follow dollar million interest cost incur capitalize construction interest expense interest income foreign exchange lossesgain net gain sale divest product realize gain foreign currency option net ineffective portion interest rate swap net total expenseincome net september scheringplough complete previously announce divestiture certain animal health product require regulatory agency europe connection acquisition obs result divestitures scheringplough recognize gain million million tax addition scheringplough recognize gain million million tax sale manufacturing site net cash proceed divest animal health product million scheringplough participate health care refinancing program adopt local government fiscal authority major european market scheringplough transfer million million respectively trade account receivables own foreign subsidiary thirdparty financial institution recourse transfer trade account receivable qualified sale account receivable sfas accounting transfer service financial asset extinguishment liability transfer trade account receivable material impact schering plough statement consolidated operation cash flow transaction include change account receivable operating activity net foreign exchange gain million include million foreign currency transaction exchange loss relate euro denominate debt instrument prior account economic hedge net investment foreign operation currency exchange loss noncash item table content note consolidated financial statement continue include adjustment reconcile net loss net cash provide operating activity statement consolidated cash flow overall risk management strategy consideration preliminary financing scenario associate acquisition obs scheringplough purchase eurodenominate currency option derivative aggregate premium approximately million receive proceed million termination option result net realize gain million derivative qualify hedge accounting accordance sfas accounting derivative instrument hedge activity amend sfas accordingly gain derivative recognize statement consolidated operation derivative shortterm trading nature hedge specific financing invest transaction accordingly cash impact derivative classified operating cash flow statement consolidated cash flow derivative terminate fourth quarter scheringplough execute series interest rate swap anticipation financing acquisition obs objective swap hedge interest rate payment future issuance debt swap designate cash flow hedge future interest rate payment accordance sfas effective portion gain loss hedge report comprehensive income ineffective portion report operation connection eurodenominate debt issuance describe note borrowing commitment portion swap deem ineffective scheringplough recognize million loss statement consolidated operation effective portion swap million record comprehensive income recognize interest expense life relate debt cash flow impact interest rate swap classify operating cash flow statement consolidated cash flow income taxis component consolidate incomeloss income taxis year end december follow dollar millions united states foreign net incomeloss income taxis include cumulative effect change accounting principle net incomeloss include amortization fair value certain asset acquire obs acquisition net loss include charge acquire inprocess research development billion connection acquisition obs income cholesterol joint venture include table base jurisdiction income earn table content note consolidated financial statement continue component income tax expense year end december follow deral tate reign otal dollar millions current defer total current defer total current defer total scheringplough establish valuation allowance net defer tax asset include benefit operating loss management conclude likely benefit net defer tax asset realize december scheringplough continue maintain valuation allowance net defer tax asset scheringplough maintain intent indefinitely reinvest earning international subsidiary scheringplough provide defer taxis approximately billion undistributed foreign earning december determine tax liability arise earning remit practicable liability depend number factor include earning distribute operation generate taxable profit loss defer income taxis provide temporary difference financial reporting basis tax basis scheringplough asset liability scheringplough defer tax asset result principally record certain item currently deductible tax purpose net operating loss tax credit carryforward scheringplough defer tax liability principally result book tax basis difference result obs acquisition use accelerate depreciation tax purpose table content note consolidated financial statement continue component scheringploughs defer tax asset liability december follow dollar million defer tax asset nol carryforward tax credit carryforward postretirement employee benefit inventory relate sale return reserve litigation accrual intangible asset total defer tax asset defer tax liability depreciation inventory valuation obs intangible asset total defer tax liability defer tax valuation allowance net defer tax liability defer tax asset net operating loss tax credit carryforward principally relate nol research development tax credit foreign tax credit federal alternative minimum tax amt credit carryforward december scheringplough approximately billion nol income tax purpose available offset future taxable income nol operate loss adjust difference financial tax report nol expire vary amount unused state nol relate nol expire vary amount december scheringplough approximately million tax credit carryforward expire million foreign tax credit carryforward expire million amt tax credit carryforward indefinite life nol carryforward materially reduce examination scheringplough income tax return internal revenue service irs scheringplough reduce defer tax asset relate valuation allowance record nol tax credit carryforward reflect estimate resolution examination table content note consolidated financial statement continue difference income taxis base statutory tax rate scheringploughs income tax expense year end december follow dollar million income tax expensebenefit statutory rate increasedecrease taxis result low rate jurisdiction net operating loss tax benefit record permanent difference state income tax provision tax matter income tax effective tax rate permanent difference largely attributable acquire inprocess research development charge billion relate acquisition obs tax benefit record low tax rate jurisdiction net primarily attributable scheringplough manufacturing subsidiary singapore ireland puerto rico operate incentive tax grant begin expire additionally major country schere plough conduct operation statutory tax rate tax rate overall income taxis primarily relate foreign taxis include benefit relate operating loss scheringplough implement provision fasb interpretation accounting uncertainty income taxis fin january require fin cumulative effect apply provision interpretation report adjustment scheringplough retain earning balance january scheringplough reduced january retain earning million result adoption fin scheringploughs unrecognized tax benefit result primarily vary application statute regulation interpretation include exposure intercompany term cross border arrangement utilization cash hold foreign subsidiary investment property scheringplough tax matter litigation note legal environmental regulatory matter december total unrecognized tax benefit million million respectively include tax liability reduction defer tax asset carry valuation allowance december approximately million million respectively total unrecognized tax benefit recognize affect effective tax rate management believe reasonably possible total unrecognized tax benefit decrease twelvemonth period approximately million primarily attributable decision tax matter currently litigate newark district court decision render possible final resolution scheringplough examination irs appeal possible resolution matter time ultimate resolution scheringplough tax matter payment receipt relate cash dependent number factor outside scheringploughs control scheringplough include interest expense income potential penalty uncertain tax position component income tax expense statement consolidated operation total interest expense relate uncertain tax position year end december million million respectively total accrue interest relate uncertain tax position december million million respectively include accrue liability table content note consolidated financial statement continue tabular reconciliation scheringplough fin unrecognized tax benefit year end december follow dollar millions january addition tax position relate current year addition tax position relate prior year addition tax position relate acquire entity reduction relate amount settle tax authority reduction tax position relate prior year reduction potential refund claim december scheringplough consider file refund claim base court decision involve claim right doctrine court appeal decision clarify law area clear scheringplough prevail claim unrecognized tax benefit reduce accordingly impact net loss net consolidated income tax payment exclusive payment relate tax examination litigation discuss million million million respectively second quarter irs complete examination scheringplough federal income tax return schere plough seek resolution issue raise examination irs administrative appeal process july schering plough payment million irs pertain examination scheringplough remain open irs tax year irs commence examination federal income tax return examination expect complete significant tax jurisdiction state foreign scheringploughs income tax return open examination period october irs auditor assert interest rate swap scheringplough enter unrelated party recharacterize loan affiliate company result additional tax liability tax year september scheringplough payment irs million income tax million interest scheringplough file refund claim tax interest irs december follow irss denial scheringplough claim refund scheringplough file suit district court district new jersey refund tax interest refund litigation try newark district court decision render scheringplough tax reserve adequate cover abovementione payment retirement plan postretirement benefit plan description scheringplough define benefit pension plan cover eligible employee certain foreign country large plan scheringplough retirement plan benefit normal retirement primarily base participant average final earning year service social security income modify early retirement death disability benefit available plan benefit fully vest year service plan provide continue accrual table content note consolidated financial statement continue credit service employee opt postpone retirement remain employed scheringplough reach normal retirement age large international definedbenefit plan dutch plan scheringplough pension fund provide benefit normal retirement age base primarily participant average earning year service benefit take account social security equivalent income postponement retirement option local dutch regulation benefit modify early retirement death disability benefit available plan nonus pension plan offer benefit competitive local market condition define benefit plan assume scheringplough obs acquisition include scheringploughs consolidated result operation consolidated financial position acquisition date financial position december note acquisition addition scheringplough provide postretirement medical life insurance benefit primarily eligible retiree dependents postretirement benefit plan certain country provide postretirement benefit plan effective december scheringplough account retirement plan postretirement benefit plan plan accordance sfas employer account define benefit pension postretirement plan sfas sfas require recognition asset overfunde plan liability underfunde plan scheringplough consolidated balance sheet statement require recognition change fund status plan year change occur scheringploughs definedbenefit pension postretirement plan december measurement date include scheringplough accumulate comprehensive loss december billion billion net tax effect million million net tax effect respectively cost recognize component net periodic benefit cost pursuant sfas employer account pension sfas employer account postretirement benefit pension component cost december follow oth pos retirement retirement plan benefit dollar million actuarial loss prior service costcredit total actuarial loss primarily represent cumulative difference actuarial assumption actual return plan asset change discount rate plan experience total loss amount net excess certain threshold amortize net pension postretirement benefit cost average remain service life employee amount accumulate comprehensive loss expect recognize component net periodic cost follow retirement postretirement plan benefit dollar million actuarial loss recognition prior service costcredit recognition table content note consolidated financial statement continue actuarial assumption consolidated weight average assumption determine benefit obligation december ret eman othe postr etireme plan benefit benefit plan discount rate rate increase future compensation international benefit plan discount rate rate increase future compensation scheringploughs international postretirement benefit plan argentina brazil canada south africa assumption develop benefit obligation yearend consolidated weight average assumption determine net benefit cost year end december pos tre emen retirement plan benefit benefit plan discount rate longterm expect rate return plan asset rate increase future compensation international benefit plan discount rate longterm expect rate return plan asset rate increase future compensation assumption determine net periodic benefit cost year establish end previous year assumption determine benefit obligation establish yearend net periodic benefit cost actuarial present value benefit obligation base actuarial assumption determine annually base evaluation longterm trend market condition impact cost provide retirement benefit longterm expect rate return plan asset derive return assumption determine major asset class equity fix income real estate proportional basis return expectation asset class base largely assumption economic growth inflation support longterm historical datum weight average assume healthcare cost trend rate postretirement measurement purpose percent trend percent percent increase assume healthcare cost trend rate increase combined postretirement service interest cost million postretirement benefit obligation million percent decrease assume health care cost trend rate decrease combined postretirement service interest cost million postretirement benefit obligation million average retirement age assume base annual rate retirement experience scheringplough table content note consolidated financial statement continue component net periodic benefit cost net pension postretirement periodic benefit cost total million million million respectively component net pension postretirement periodic benefit cost follow pos tre tir ement retirement plan benefit dollar million service cost interest cost expect return plan asset amortization net termination benefit settlement net pension postretirement periodic benefit cost net pension postretirement periodic benefit cost attributable retirement postemployment benefit plan million million million benefit obligation component change benefit obligation follow ther tretir ement retirement plan benefit dollar million benefit obligation begin year service cost interest cost medicare drug subsidy receive participant contribution effect exchange rate change benefit pay acquisitionsplan transfer actuarialgainslosse include assumption change change measurement date plan amendment termination benefit curtailment settlement benefit obligation end year benefit obligation overfunde plan benefit obligation underfunde plan benefit obligation plan retirement benefit postretirement benefit billion billion table content note consolidated financial statement continue fund status balance sheet presentation component change plan asset follow ther tretir ement retirement plan benefit dollar million fair value plan asset primarily stock bond begin year actual lossgain plan asset employer contribution participant contribution acquisitionsplan transfer change measurement date effect exchange rate change settlement benefit pay fair value plan asset end year plan asset overfunde plan plan asset underfunde plan fair value pension postretirement benefit plan asset billion billion reduction fair value plan asset december compare december condition worldwide debt equity market deteriorate significantly condition negative effect fair value plan asset addition plan asset indicate december security investment million million respectively hold nonqualified trust designate provide pension benefit certain underfunde plan accordance sfas december net asset overfunde plan million million respectively relate scheringplough retirement plan include longterm asset accompany consolidated balance sheet net liability underfunde plan december total billion billion respectively follow ther tretir ement retirement plan benefit dollar millions accrue compensation current longterm liability total december accumulate benefit obligation abo retirement plan billion billion respectively aggregate accumulate benefit obligation fair value plan asset retirement plan accumulate benefit obligation excess plan asset table content note consolidated financial statement continue billion billion respectively december billion billion respectively december plan asset fair value asset allocation consolidated retirement plan december target allocation follow ntage target plan asset allocation december asset category equity security debt security real estate total asset allocation postretirement benefit trust december target allocation follow ntage target plan asset allocation december asset category equity security debt security total scheringplough investment relate plan broadly diversify consist primarily equity fix income security objective generate longterm investment return consistent acceptable level overall portfolio market value risk asset periodically rebalance target allocation estimate future benefit payment follow benefit payment reflect expect future service appropriate expect pay etirement ther postretirement plan benefit dollar million year scheringplough practice fund qualified pension plan sufficient amount meet minimum requirement set forth applicable law scheringplough expect contribute approximately million retirement plan include approximately million scheringplough retirement plan table content note consolidated financial statement continue define contribution plan scheringplough maintain define contribution saving plan include plan acquire obs acquisition large plan scheringplough make contribution plan equal percent eligible employee earning plus matching contribution percent eligible employee earning base employee contribution total scheringplough contribution plan million million million respectively scheringplough maintain define contribution retirement plan jurisdiction scheringplough contribution plan material earningsloss common share follow table reconcile component basic dilute earningsloss share computation dollar share million eps numerator net incomeloss available common shareholder eps denominator weight average share outstanding basic eps dilutive effect option defer stock unit average share outstanding diluted eps year end december approximately million common share obtainable conversion mandatory convertible preferred stock exclude computation dilute earningsloss common share effect antidilutive quarter scheringplough mandatory convertible preferred stock convert million common share common share include weight average share calculation period conversion year end december million million common share respectively obtainable conversion mandatory convertible preferred stock exclude computation dilute earningsloss common share effect antidilutive weight average basis period prior conversion common share issuable scheringploughs stock incentive plan exclude computation dilute earningsloss common share antidilutive effect million million million respectively year end december respectively scheringplough issue common share august common share include weightedaverage share calculation period issuance note shareholder equity additional information table content note consolidated financial statement continue accumulate comprehensive loss component accumulate comprehensive loss december follow dollar million foreign currency translation adjustment pension postretirement liability net tax effect accordance sfas provision accumulate derivative loss unrealize lossgain investment available sale net tax total include foreign currency translation adjustment gain million loss million respectively scheringplough eurodenominate debt instrument designate effective economic hedge net investment foreign operation scheringplough execute series interest rate swap anticipation financing acquisition obs objective swap hedge interest rate payment future issuance debt swap designate cash flow hedge future interest rate payment accordance sfas effective portion gain loss hedge report comprehensive income ineffective portion report operation effective portion swap million record comprehensive income recognize interest expense life relate debt year end december million million respectively effective portion interest rate swap recognize interest expense million expect recognize interest expense gross unrealized pretax loss investment million gain million inventory inventory consist follow december dollar million finish product good process raw material supply total inventory inventory classify noncurrent asset overall decrease total inventory primarily amortization fair value stepup record obs acquisition million million respectively include depreciation amortization consolidate statement cash flow include asset december million million respectively inventory expect sell year inventory value lastin firstout lifo basis comprise approximately percent percent total inventory december respectively estimate replacement cost total inventory december billion billion respectively cost inventory determine firstin firstout method fifo table content note consolidated financial statement continue goodwill intangible asset purchase accounting acquisition obs scheringplough record billion goodwill billion assign prescription pharmaceutical segment million assign animal health segment goodwill relate obs acquisition deductible income tax purpose follow table summarize goodwill activity year end december consumer consumer prescription animal health prescription animal health pharmaceutical health care total pharmaceutical health care total dollar million goodwill balance january acquisition foreign exchange adjustment obs purchase accounting goodwill balance december component intangible asset net follow december gross gross carrying accumulate carry accumulate amortization net amortization net dollar million patent trademark license total intangible asset patent trademark license amortize straightline method respective useful life residual value intangible asset estimate zero purchase accounting acquisition obs scheringplough record billion intangible asset note acquisition additional information amortization expense relate intangible asset million million million respectively include cost sale statement consolidated operation intangible asset review determine recoverability compare carry value expect undiscounted future cash flow event circumstance warrant review annual amortization expense relate intangible asset year expect approximately million product license december scheringplough centocor revise distribution agreement development commercialization distribution remicade golimumab extend scheringploughs right exclusively market remicade match duration scheringplough exclusive marketing right golimumab effective regulatory approval golimumab scheringploughs marketing right product extend year commercial sale golimumab centocor receive progressively increase share profit scheringplough distribution product scheringplough marketing territory table content note consolidated financial statement continue share profit remain fixed remainder term change duration remicade marketing right profit share arrangement product condition approval golimumab grant prior september scheringplough independently develop market golimumab crohns disease indication territory option centocor participate addition scheringplough centocor agree utilize autoinjector device commercialization golimumab agree share development cost right device scheringplough upfront payment million include research development expense accompany statement consolidated operation year end december borrowing commitment short longterm borrowing scheringplough outstanding borrowing december follow dollar millions shortterm commercial paper shortterm borrowing current portion longterm debt current portion capital lease total shortterm borrowing longterm senior unsecured eurodenominate note float rate unsecured eurodenominate term loan senior unsecured note senior unsecured eurodenominate note senior unsecured note senior unsecured note senior unsecured note capital lease longterm borrowing total longterm borrowing scheringplough shortterm borrowing consist primarily bank loan commercial paper issue weight average interest rate shortterm borrowing percent percent december respectively senior unsecured note october scheringplough issue euro million aggregate principal percent senior unsecured euro denominate note euro billion aggregate principal percent senior unsecured eurodenominate note net proceed offer approximately billion interest note payable annually effective interest rate percent senior unsecured eurodenominate note percent senior unsecured eurodenominate note incorporate initial discount debt issuance fee impact interest rate hedge percent percent respectively interest rate payable note subject adjustment note generally restrict scheringplough creating assume lien enter sale leaseback transaction aggregate outstanding indebtedness secure lien relate table content note consolidated financial statement continue sale leaseback transaction exceed percent consolidate net tangible asset note redeemable scheringplough option time redemption price specify prospectus change control trigger event occur certain circumstance define prospectus holder note right require scheringplough repurchase note cash payment equal percent aggregate principal note repurchase plus accrue unpaid interest date purchase september scheringplough issue billion aggregate principal percent senior unsecured note billion aggregate principal percent senior unsecured note net proceed offer approximately billion interest note payable semiannually effective interest rate percent senior unsecured note percent senior unsecured note incorporate initial discount debt issuance fee percent percent respectively interest rate payable note subject adjustment note generally restrict scheringplough creating assume lien enter sale leaseback transaction aggregate outstanding indebtedness secure lien relate sale leaseback transaction exceed percent consolidate net tangible asset note redeemable scheringplough option time redemption price equal great percent principal note sum present value remain schedule payment principal interest discount redemption date semiannual basis rate treasury note comparable remain term plus basis point note basis point note change control trigger event occur certain circumstance define prospectus holder note right require scheringplough repurchase note cash payment equal percent aggregate principal note repurchase plus accrue unpaid interest date purchase scheringplough net proceed issuance senior unsecured note fund portion purchase price obs acquisition note acquisition november scheringplough issue billion aggregate principal percent senior unsecured note billion aggregate principal percent senior unsecured note net proceed offer billion interest note payable semiannually subject rate adjustment follow rating assign particular series note moodys investors service inc moodys standard poor rating service change rating set forth interest rate payable series note initial interest rate percent note percent note plus additional interest rate set forth moodys additional interest rate moodys rating rating baa bbb baa bbb baa bbb event interest rate note increase percent initial coupon rate percent percent respectively moodys subsequently upgrade rating interest rate correspondingly reduce percent percent respectively furthermore interest rate payable particular series note return percent percent respectively rate adjustment provision permanently cease apply follow downgrade moodys respectively note subsequently rate baa moodys bbb table content note consolidated financial statement continue issuance note rate moodys july moodys lower rating note baa accordingly interest payable note increase basis point effective december result percent interest rate payable note percent interest rate payable note december note rate baa moodys senior unsecured note redeemable scheringplough option time redemption price equal great percent principal note sum present value remain schedule payment principal interest discount rate treasury note comparable remain term plus basis point note basis point note term loan october scheringplough enter fiveyear senior unsecured eurodenominate term loan facility syndicate bank october scheringplough draw euro billion billion term loan fund portion purchase price obs acquisition note acquisition additional information term loan float interest rate weight average rate respectively require scheringplough maintain net debt total capital ratio percent percent net debt equal total debt cash cash equivalent shortterm investment marketable security total capital equal sum total debt total shareholder equity exclude cumulative effect acquire process research development connection acquisition consummate closing term loan term loan generally restrict scheringplough creating assume lien enter sale leaseback transaction aggregate outstanding indebtedness secure lien relate sale leaseback transaction exceed percent consolidate net tangible asset scheringplough early principal repayment euro million prepayment penalty incur relate principal repayment addition scheringplough international subsidiary approximately million available unused line credit uncommitte financial institution december aggregate maturitie aggregate maturity longterm debt december year follow ereafter dollar millions longterm debt credit facility august scheringplough enter billion revolving credit agreement syndicate bank terminate billion credit facility mature credit facility float interest rate mature august require scheringplough maintain net debt total capital ratio percent percent net debt equal total debt cash cash equivalent shortterm investment marketable security total capital equal sum total debt total shareholder equity exclude cumulative effect acquire inprocess research development connection acquisition consummate closing credit facility credit facility generally restrict scheringplough creating assume lien enter sale leaseback transaction aggregate outstanding indebtedness secure lien relate sale leaseback transaction exceed percent consolidated table content note consolidated financial statement continue net tangible asset credit line available general corporate purpose consider support scheringplough commercial paper borrowing borrowing credit facility draw parent company whollyowne international subsidiary accompany parent guarantee facility require compensating balance nominal commitment fee pay december borrowing outstanding facility commitment total rent expense amount million million million respectively future annual minimum rental commitment year noncancelable operating lease december follow million million million million million aggregate minimum lease obligation million december scheringplough commitment total million million relate capital expenditure respectively financial instrument sfas require derivative record balance sheet fair value addition statement require effective portion qualify cash flow hedge recognize income hedge item affect income change fair value derivative qualify fair value hedge change fair value hedge risk recognize occur change fair value derivative qualify hedge treatment ineffective portion qualifying hedge recognize statement consolidated operation occur risk policy objective scheringplough expose market risk primarily change foreign currency exchange rate less extent interest rate equity price change currently scheringplough deem cost effective engage formulabase program hedge profit cash flow international operation derivative financial instrument limit basis scheringplough hedge selective foreign currency risk derivative scheringplough international subsidiary purchase significant quantity inventory payable dollar manage level inventory relate payable rate inventory turnover provide natural level protection adverse change exchange rate furthermore risk adverse exchange rate change somewhat mitigated fact scheringplough international operation widespread scheringplough senior unsecured eurodenominate note eurodenominate term loan designate effective economic hedge net investment foreign operation accordance sfas foreign currency translation foreign currency transaction gain loss eurodenominate debt instrument include foreign currency translation adjustment comprehensive income overall risk management strategy consideration preliminary financing scenario associate acquisition obs scheringplough purchase eurodenominate currency option mitigate exposure event significant strengthening euro compare dollar scheringplough purchase option aggregate premium approximately million receive proceed million termination option result net realize gain million derivative qualify hedge accounting accordance sfas accordingly gain derivative recognize statement consolidated operation derivative shortterm trading nature hedge specific financing investment transaction accordingly cash impact derivative classified operate cash table content note consolidated financial statement continue flow statement consolidated cash flow note incomeexpense net december open foreign currency option contract scheringplough execute series interest rate swap anticipation financing acquisition obs objective swap hedge interest rate payment future issuance debt swap designate cash flow hedge future interest payment accordance sfas effective portion gain loss hedge report comprehensive income ineffective portion report operation connection eurodenominate debt issuance describe note borrowing commitment portion swap deem ineffective scheringplough recognize million loss statement consolidated operation effective portion swap million record comprehensive income recognize interest expense life relate debt cash flow related interest rate swap classify operating cash flow statement consolidated cash flow note expenseincome net december open interest rate swap scheringplough mitigate credit risk derivative instrument deal counterpartie consider high credit quality accordingly scheringplough anticipate loss nonperformance scheringplough enter derivative instrument manner generate trading profit scheringplough classifie cash flow derivative account hedge category item hedge fair value financial instrument table present carry value estimate fair value certain scheringplough financial instrument december estimate fair value determine base market price available dealer quote carry value financial instrument include cash cash equivalent approximate estimate fair value december carry estimate carry estimate value fair value value fair value dollar million asset shortterm investment longterm investment liabilitie shortterm borrowing current portion longterm debt longterm debt longterm investment longterm investment include noncurrent asset primarily consist debt equity security hold non qualified trust fund longterm employee benefit obligation longterm employee benefit obligation include liability consolidated balance sheet asset fund relate employee benefit obligation table content note consolidated financial statement continue fair value measurement scheringplough consolidated balance sheet december include follow asset liability measure fair value recur basis uoted price active market total identical significant significant fair value asset observable unobservable december liability input input level level level dollar million asset security hold employee compensation total asset liability foreign currency exchange contract total liability majority scheringplough asset liability measure fair value recur basis measure unadjusted quote price active market identical item level input multiply number unit hold balance sheet date december asset liabilitie fair value measure significant observable input level include measurement quote price identical item market active measurement input derive principally corroborate observable market datum shareholder equity prefer share december scheringplough authorize share prefer stock consist preferred share designate percent mandatory convertible preferred stock prefer share designation determined december share percent mandatory convertible preferred stock issue outstanding mandatory convertible preferred stock august scheringplough issue share percent mandatory convertible preferred stock prefer stock face value billion net proceed scheringplough approximately billion deducting commission discount underwriting expense scheringplough net proceed sale prefer stock fund portion purchase price obs acquisition note acquisition additional information share prefer stock automatically convert common share scheringplough depend average closing price scheringplough common share trading day period end trading day prior mandatory conversion date august define prospectus prefer shareholder elect convert time prior august minimum conversion ratio common share share prefer stock additionally time prior mandatory conversion date closing price scheringplough common share exceed trading day period consecutive trading day scheringplough elect cause conversion table content note consolidated financial statement continue preferred stock outstanding minimum conversion ratio common share share preferred stock share liquidation preference share plus equal sum accrue cumulate unpaid dividend prefer stock accrue dividend annual rate percent share outstanding dividend cumulative date issuance extent scheringplough legally permit pay dividend board director declare dividend payable scheringplough pay dividend dividend payment date dividend payment date february august november year dividend pay november mandatory convertible prefer stock year end december share percent mandatory convertible preferred stock issue august preferred stock convert share scheringplough common stock follow conversion share prefer stock resume status authorize unissued preferred stock undesignate series available future issuance equity issuance treasury share august scheringplough issue common share treasury share share net proceed scheringplough approximately billion deducting commission discount underwriting expense scheringplough net proceed sale common share fund portion purchase price obs acquisition note acquisition additional information summary treasury share transaction year end december follow share millions share balance january issuance common share stock incentive plan activity share balance december include treasury share balance million share acquire subsidiary scheringplough open market purchase program share consider treasury share new jersey law like treasury share vote consider outstanding share determine necessary vote approve matter submit stockholder vote subsidiary receive dividend share effective september board director scheringplough adopt amend restate certificate incorporation reflect automatic conversion prefer stock issue share common stock september term prefer stock insurance coverage scheringplough maintain insurance coverage deductible selfinsurance management believe adequate need current circumstance coverage reflect market condition include cost availability exist time write relationship insurance coverage selfinsurance vary accordingly scheringplough selfinsure substantially risk relate product liability availability commercial insurance restrictive scheringplough continually assess good way provide insurance need table content note consolidated financial statement continue segment information scheringplough reportable segment prescription pharmaceutical animal health consumer health care segment sale profitloss datum follow consistent scheringplough current management reporting structure prescription pharmaceutical segment discover develop manufacture market human pharmaceutical product animal health segment discover develop manufacture market animal health product consumer health care segment develop manufacture market overthecounter foot care sun care product primarily net sale major product segment dollar million prescription pharmaceutical remicade nasonex temodar pegintron clarinexaerius follistimpuregon nuvare claritin avelox integrilin caelyx rebetol zemuron remeron intron subutexsuboxone asmanex pharmaceutical animal health consumer health care otc foot care sun care consolidate net sale product acquire obs acquisition november table content note consolidated financial statement continue net sale geographic area dollar millions united states europe canada latin america asia pacific consolidated net sale scheringplough subsidiary country outside net sale present geographic area scheringplough customer locate follow foreign country account percent consolidated net sale past year consolidated consolidated consolidated net sale net sale net sale net sale net sale net sale dollar million total international net sale france japan germany canada net sale customer sale single customer account percent scheringploughs consolidate net sale past year follow consolidated consolidated consolidated net sale net sale net sale net sale net sale net sale dollar million mckesson corporation cardinal health profitloss segment yea end decem dollar million prescription pharmaceutical animal health consumer health care corporate include net interest expenseincome million million million respectively consolidated profitloss tax cumulative effect change accounting principle table content note consolidated financial statement continue prescription pharmaceutical segment profit include charge arise purchase accounting item million animal health segment profit include charge arise purchase accounting item million prescription pharmaceutical segment loss include billion purchase accounting item include acquire inprocess research development billion animal health segment loss include million purchase accounting item include acquire inprocess research development million profit animal health segment include gain sale certain animal health product million scheringplough net sale include sale vytorin zetia manage joint venture merck scheringplough account joint venture equity method accounting note equity income additional information prescription pharmaceutical segment include equity income merckscheringplough joint venture corporate include interest income expense foreign exchange gain loss currency option gain headquarters expense special charge miscellaneous item accounting policy segment report describe note summary significant accounting policy corporate include special acquisitionrelate charge million comprise million integration relate cost million employee termination cost relate productivity transformation program include ongoing integration obs estimate charge relate reportable segment follow prescription pharmaceutical million animal health million consumer health care million corporate million corporate include special acquisitionrelate charge million comprise million integration relate cost obs acquisition million employee termination cost integration activity estimate charge relate reportable segment follow prescription pharmaceutical million animal health million corporate million corporate include special charge million primarily relate change scheringploughs manufacturing operation puerto rico announce june relate prescription pharmaceutical segment include cost sale charge approximately million manufacturing streamlining action primarily relate prescription pharmaceutical segment note special acquisitionrelate charge manufacture streamline additional information supplemental sale information sale product comprise percent scheringplough international sale year end december follow ercentage applicable sale dollar million nasonex international remicade table content note consolidated financial statement continue longlived asset geographic location dollar millions united states netherlands ireland singapore total longlived asset show geographic location primarily property significant increase longlive asset december obs acquisition scheringplough disaggregate asset segment basis internal management report information present legal environmental regulatory matter background scheringplough involve claim investigation legal proceeding scheringplough record liability contingency probable liability incur reasonably estimate scheringplough adjust liability contingency reflect current good estimate probable loss minimum liability case well estimate determinable scheringplough record minimum probable range liability expect insurance recovery consider determine amount record liability environmental relate matter scheringplough believe loss contingency reasonably possible probable loss estimate liability record liability reasonably possible disclosure loss contingency scheringplough review status claim investigation legal proceeding ongoing basis include related insurance coverage time time scheringplough settle resolve matter term condition management believe good interest scheringplough resolution claim investigation legal proceeding individually aggregate material adverse effect scheringplough consolidated result operation cash flow financial condition matter discuss remainder note record liability contingency december relate expense incur year end december material opinion management base advice legal counsel ultimate outcome matter matter discuss remainder note expect material impact scheringplough consolidated result operation cash flow financial condition patent matter intellectual property protection critical scheringplough ability successfully commercialize product innovation potential litigation scheringploughs intellectual property right exist initiate party attempt abridge scheringplough right scheringplough protect right table content note consolidated financial statement continue awp litigation investigation scheringplough continues respond exist new litigation certain state private payor investigation department health human services department justice state industry scheringplough practice average wholesale price awp scheringplough cooperating investigation litigation investigation relate awp pharmaceutical company certain drug improperly exceed average price pay provider consequence result unlawful inflation certain reimbursement drug state program private payor base awp complaint allege violation federal state law include fraud medicaid fraud consumer protection violation claim majority case plaintiff seek class certification case class certify outcome litigation investigation include substantial damage imposition substantial fine penalty injunctive administrative remedy security class action litigation federal security litigation follow scheringploughs announcement fda conduct inspection scheringplough manufacture facility new jersey puerto rico issue report cite deficiency concern compliance current good manufacturing practice lawsuit file scheringplough certain name officer lawsuit allege defendant violate federal security law allegedly fail disclose material information make material misstatement specifically allege schering plough fail disclose allege risk new drug application clarinex delay result manufacturing issue allege scheringplough fail disclose allege depth severity manufacturing issue complaint consolidate action district court district new jersey consolidated amend complaint file october purport represent class shareholder purchase share scheringplough stock february complaint seek compensatory damage behalf class court certify shareholder class october notice pendency class action send member class july february court sign order preliminarily approve settlement agreement propose settlement agreement schedule present final approval hearing june erisa litigation march scheringplough serve putative class action complaint file district court new jersey allege scheringplough retire chairman ceo president richard jay kogan scheringploughs employee saving plan plan administrator current director certain corporate officer breach fiduciary obligation certain participant plan complaint seek damage loss allegedly suffer plan complaint dismiss june plaintiff appeal august court appeal circuit reverse dismissal district court matter remand district court proceeding kdur antitrust litigation scheringplough settle patent litigation upshersmith inc upshersmith esi lederle inc lederle relate generic version kdur scheringploughs longacte potassium chloride product supplement cardiac patient lederle upsher smith file abbreviate new drug application follow commencement ftc administrative proceeding allege anti competitive effect settlement resolve scheringplough favor allege class action table content note consolidated financial statement continue suit file federal state court behalf direct indirect purchaser kdur scheringplough upshersmith lederle suit claim violation federal state antitrust law state statutory common law cause action suit seek unspecified damage february special master recommend district court district new jersey dismiss class action lawsuit summary judgment thirdparty payor action purport class action litigation file follow announcement settlement massachusetts investigation plaintiff action seek damage behalf thirdparty payor result allegation offlabel promotion improper payment physician issue massachusetts investigation litigation investigation relate merckscheringplough cholesterol joint venture background january merckscheringplough cholesterol joint venture announce result enhance clinical trial effect combination ezetimibe highdose simvastatin simvastatin atherosclerotic process patient heterozygous familial hypercholesterolemia july merckscheringplough cholesterol joint venture announce result sea clinical trial simvastatin ezetimibe aortic stenosis litigation investigation respect matter relate clinical trial ongoing scheringplough cooperate fully investigation respond request information scheringplough intends vigorously defend lawsuit file relate enhance study investigation inquiry february scheringplough joint venture andor joint venture partner merck receive number governmental inquiry subject number investigation relate enhance clinical trial include letter congress include subcommittee oversight investigation house committee energy commerce rank minority member senate finance committee collectively seek combination witness interview document information variety issue relate merckscheringplough cholesterol joint venture enhance clinical trial include subpoena state official include state attorney general request information attorney department justice seek similar information document addition scheringplough receive letter subcommittee oversight investigation house committee energy commerce seek certain information document relate seas clinical trial matter scheringplough merck joint venture cooperating investigation respond inquiry january initial release enhance datum fda state review result enhance trial january fda announce result review fda state follow year treatment carotid artery thickness increase vytorin group simvastatin group difference change carotid artery thickness group statistically significant level ldl cholesterol decrease vytorin group decrease simvastatin group difference reduction ldl cholesterol group statistically significant fda state result enhance change position elevate ldl cholesterol risk factor cardiovascular disease lower ldl cholesterol reduce risk table content note consolidated financial statement continue cardiovascular disease fda state pende result improveit clinical trial patient stop take vytorin cholesterol lower medication talk doctor question litigation scheringplough continues respond exist new litigation include civil class action lawsuit allege common law state consumer fraud claim connection scheringplough sale promotion merckscheringplough jointventure product vytorin zetia putative shareholder security class action lawsuit officer name defendant allege false misleading statement omission scheringplough representative relate timing disclosure concern enhance result allegedly violation section securities exchange act putative shareholder security class action lawsuit officer director name allege material misstatement omission relate enhance result offer document connection scheringplough security offering allegedly violation security act include section putative class action suit allege scheringplough certain officer director breach fiduciary duty erisa seek damage loss allegedly suffer plan shareholder derivative action allege board director breach fiduciary obligation relate timing release enhance result letter behalf single shareholder request board director investigate allegation litigation describe warrant bring appropriate legal action behalf scheringplough tax matter october irs auditor assert interest rate swap scheringplough enter unrelated party recharacterize loan affiliate company result additional tax liability tax year september scheringplough payment irs million income tax million interest scheringplough file refund claim tax interest irs december follow irss denial scheringplough claim refund scheringplough file suit district court district new jersey refund tax interest refund litigation try newark district court decision render scheringplough tax reserve adequate cover abovementione payment pende administrative obligation connection settlement investigation department justice attorney office eastern district pennsylvania scheringplough enter fiveyear corporate integrity agreement cia cia amend august connection settlement massachusetts investigation commence new fiveyear term failure comply obligation cia result financial penalty date scheringplough believe comply obligation matter product liability beginning number complaint file jurisdiction assert claim organon usa inc organon pharmaceuticals usa inc organon international organon scheringplough corporation arise organon marketing sale nuvare combine hormonal contraceptive vaginal ring plaintiff contend organon scheringplough fail adequately warn allege increase risk venous thromboembolism vte pose nuvare andor downplay risk vte plaintiff seek damage injury allegedly sustain product use include alleged death heart attack stroke majority case currently pende federal multidistrict litigation venue missouri new jersey state court case pende state table content note consolidated financial statement continue french matter base complaint french competition authority competitor france pursuant court order french competition authority obtain document french subsidiary scheringplough relate subutex product subsidiary market sell resolution matter adverse french subsidiary result imposition civil fine injunctive administrative remedy july juge des libert dtention order annulment search seizure procedural ground july french authority appeal order french supreme court april competitor request interim relief portion grant french competition authority december interim relief require scheringploughs french subsidiary publish specialized newspaper information include generic quantitative qualitative composition pharmaceutical form substitutable subutex february paris court appeal confirm decision french competition authority january french supreme court confirm decision french competition authority environmental scheringplough responsibility environmental cleanup state local federal law include comprehensive environmental response compensation liability act commonly know superfund superfund site equivalent site state law scheringplough allege potentially responsible party prp scheringplough believe remote time material liability relation site scheringplough estimate obligation cleanup cost superfund site base information obtain federal environmental protection agency epa equivalent state agency andor study prepare independent engineer probable cost pay prps scheringplough record liability environmental assessment andor cleanup probable loss incur reasonably estimate table content report independent register public accounting firm board director shareholder scheringplough corporation audit accompany consolidated balance sheet scheringplough corporation subsidiary company december relate statement consolidated operation shareholder equity cash flow year period end december audits include financial statement schedule list index item schedule valuation qualifying account financial statement financial statement schedule responsibility company management responsibility express opinion financial statement financial statement schedule base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidate financial statement present fairly material respect financial position scheringplough corporation subsidiary december result operation cash flow year period end december conformity accounting principle generally accept united states america opinion financial statement schedule consider relation basic consolidated financial statement take present fairly material respect information set forth discuss note consolidated financial statement effective december company adopt statement financial accounting standard employer account define benefit pension postretirement plan discuss note consolidated financial statement effective january company adopt financial accounting standard board interpretation accounting uncertainty income taxis audit accordance standard public company accounting oversight board united states company internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion company internal control financial reporting deloitte touche llp parsippany new jersey february table content scheringplough corporation subsidiary quarterly datum unaudite onth nde march june september december dollar million share figure net sale cost sale gross margin sell general administrative research development acquire inprocess research development incomeexpense net special charge acquisitionrelate charge equity income cholesterol joint venture incomeloss income taxis income tax expense net incomeloss dividend prefer share net incomeloss available common shareholder dilute earningsloss common share basic earningsloss common share dividend common share common share price high low average share outstanding diluted eps million average share outstanding basic eps million complete final analysis result scheringplough determine certain income tax effect relate accounting purchase ob reflect overstatement income tax expense quarterly period total million accordingly scheringplough revise quarterly information include change result reduction income tax expense correspond increase net income net income available common shareholder associate share amount revision tax expense net income net income available common shareholder reflect table million quarter million second quarter million quarter table content operating result month period end december reflect close obs acquisition november include impact purchase accounting accordance sfas business combination dilute earning common share month period end september calculate numerator million arithmetic sum net income available common shareholder million plus dividend million relate preferred stock dilutive denominator represent average diluted share outstanding quarter note special acquisitionrelate charge manufacture change consolidate financial statement additional information relate special acquisitionrelate charge scheringplough approximate number holder record common share january item change disagreement accountant account financial disclosure applicable item control procedure management include chief executive officer chief financial officer evaluate scheringplough disclosure control procedure end period cover conclude scheringploughs disclosure control procedure effective conclude change scheringplough internal control financial reporting occur scheringplough recent fiscal quarter materially affect reasonably likely materially affect scheringploughs internal control financial reporting change business environment scheringplough operate scheringplough replace upgrade number information system commence quarter integrate organon bioscience human animal health business overall integration process ongoing year management report internal control financial reporting management scheringplough corporation responsible establish maintain adequate internal control financial reporting scheringplough internal control system design provide reasonable assurance scheringplough management board director preparation fair presentation publish financial statement internal control system matter design inherent limitation system determine effective provide reasonable assurance respect financial statement preparation presentation scheringploughs management assess effectiveness scheringploughs internal control financial reporting december make assessment management criterion set forth committee sponsor organization treadway commission coso internal control integrate framework base assessment management believe december scheringploughs internal control financial report effective scheringplough independent register public accounting firm deloitte touche llp issue attestation report effectiveness scheringploughs internal control financial reporting report follow item information applicable table content report independent register public accounting firm board director shareholder scheringplough corporation audit internal control financial reporting scheringplough corporation subsidiary company december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design supervision company principal executive principal financial officer person perform similar function effect company board director management personnel provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting include possibility collusion improper management override control material misstatement error fraud prevented detect timely basis projection evaluation effectiveness internal control financial reporting future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission audit accordance standard public company accounting oversight board united states consolidated financial statement financial statement schedule year end december company report date february express unqualified opinion financial statement financial statement schedule include explanatory paragraph company adoption statement financial accounting standard employer account define benefit pension postretirement plan financial accounting standard board interpretation accounting uncertainty income taxis deloitte touche llp parsippany new jersey february table content iii item director executive officer corporate governance information concern director nominee director incorporate reference proposal election director oneyear term scheringplough proxy statement annual meeting shareholder information concern executive officer include file caption executive officer registrant information concern compliance section exchange act incorporate reference section beneficial ownership report compliance scheringplough proxy statement annual meeting shareholder information concern audit committee audit committee financial expert incorporate reference information audit committee board director practice audit committee report scheringplough proxy statement annual meeting shareholder scheringplough adopt code business conduct ethic standard global business practice applicable employee include chief executive officer chief financial officer controller scheringploughs standard global business practice available investor relation section scheringploughs web site wwwscheringploughcom addition write copy material provide charge write office corporate secretary scheringplough corporation gallop hill road mail stop kenilworth new jersey scheringplough intend satisfy disclosure requirement item form amendment waiver provision standard global business practice post information web site address specify item executive compensation information concern executive compensation incorporate reference executive compensation scheringplough proxy statement annual meeting shareholder item security ownership certain beneficial owner management relate stockholder matter information concern security ownership certain beneficial owner management incorporate reference stock ownership scheringplough proxy statement annual meeting shareholder table content equity compensation plan information follow information relate plan equity security scheringplough issue employee director scheringplough plan equity security issue nonemployee stock incentive plan certain stock option transferable family member employeeoptionee relate trust column column number security number security issue column remain available exercise future issuance outstanding weightedaverage equity compensation option award exercise price plan exclude security plan category warrant right outstanding option reflect column equity compensation plan approve security holder stock incentive plan stock incentive plan stock incentive plan stock incentive plan director compensation plan equity compensation plan approve security holder scheringplough ireland approve profit sharing scheme organon ireland limited employee share participation scheme intervet ireland limited employee share participation scheme total plan permit eligible employee work certain scheringplough irish subsidiary enjoy tax advantage annual bonus vary percent percent pay pass trustee trustee purchase share common stock open market allocate share employee account euro defer year employee employee sell withdraw share allocate account year include share issue pursuant outstanding unearned performance award assume award earn maximum level share subject award remain unearned follow completion applicable performance period available issuance plan weight average exercise price set forth column calculate exclude performance award describe defer stock unit grant plan recipient require pay exercise price receive share subject award item certain relationship relate transaction director independence information concern certain relationship relate transaction incorporate reference certain transaction procedure relate party transaction director independence assessment scheringplough proxy statement annual meeting shareholder information concern director independence incorporate reference director independence scheringploughs proxy statement annual meeting shareholder item principal accounting fee service information concern principal accountant fee service incorporate reference proposal ratify designation deloitte touche llp audit scheringplough books account scheringplough proxy statement annual meeting shareholder table content item exhibit financial statement schedule follow document file report financial statement financial statement set forth item financial statement schedule merckscheringplough cholesterol partnership combine financial statement index age combine statement net sale contractual expense year end december combine balance sheet december combine statement cash flow year end december combine statement partner capitaldeficit year end december note combine financial statement year end december independent auditor report schedule valuation qualifying account schedule list omit applicable require table content index exhibit indicate exhibit commission file number exhibit number description location amend restate certificate incorporation incorporate reference exhibit schering plough file september amend restate bylaw incorporate reference exhibit schering plough file march right agreement scheringplough incorporate reference exhibit schering bank new york date june plough file june form participation right agreement incorporate reference exhibit schere scheringplough chase manhattan bank plough registration statement form national association trustee amendment file december file indenture date november schering incorporate reference exhibit schere plough bank new york trustee plough file november cii supplemental indenture include form note incorporate reference exhibit schering date november ploughs file november ciii second supplemental indenture include form note incorporate reference exhibit schering date november ploughs file november civ global senior note incorporate reference exhibit civ schering plough year end december global senior note incorporate reference exhibit schering plough year end december cvi supplemental indenture include form note incorporate reference exhibit schering date september plough file september cvii fourth supplemental indenture include form note incorporate reference exhibit schering date october ploughs file october directors compensation plan amend restate incorporate reference exhibit hiii schering effective june amendment plough period end september september stock incentive plan incorporate reference exhibit schering plough period end september bii amendment stock incentive plan effective incorporate reference exhibit schering february plough period end march biii amendment stock incentive plan effective incorporate reference exhibit schering february plough year end december stock incentive plan amend february incorporate reference exhibit schering plough year end december table content exhibit number description location stock incentive plan amend restate attached effective january letter agreement date november incorporate reference exhibit eiii schere robert bertolini scheringplough plough year end december eii employment agreement effective change incorporate reference exhibit schering control date december robert ploughs file december bertolini scheringplough corporation eiii amendment letter agreement employment incorporate reference exhibit schering agreement scheringplough corporation plough file december robert bertolini date december eiv employment agreement date incorporate reference exhibit schering carrie cox scheringplough plough file amendment employment agreement incorporate reference exhibit schere scheringplough corporation carrie cox date plough file december december evi employment agreement date april incorporate reference exhibit schering fred hassan scheringplough plough file april evii amendment employment agreement incorporate reference exhibit schere scheringplough corporation fred hassan date plough file december december eviii employment agreement date december incorporate reference exhibit schere thomas koestler phd schering plough year end december plough eix amendment employment agreement incorporate reference exhibit schere scheringplough corporation thomas koestler ploughs file december date december letter agreement date march thomas incorporate reference exhibit schere sabatino scheringplough plough period end march exi employment agreement effective change incorporate reference exhibit eviii control date april thomas scheringploughs year end december sabatino scheringplough exii amendment letter agreement employment incorporate reference exhibit schering agreement scheringplough corporation plough file december thomas sabatino date december exiii employment agreement date december incorporate reference exhibit eviii brent saunder scheringplough scheringplough year end december exiv amendment employment agreement incorporate reference exhibit schere scheringplough corporation brent saunder date plough file december december table content exhibit number description location exv form employment agreement effective change attach control scheringplough certain executive new agreement begin january operation management team incentive plan incorporate reference exhibit mii schering amend restate effective june plough period end september cash longterm incentive plan amend restate incorporate reference exhibit schere effective january plough year end december longterm performance share unit incentive plan incorporate reference exhibit schering amend restate effective january plough year end december transformational performance contingent share incorporate reference exhibit schering program plough year end december severance benefit plan amend restate incorporate reference exhibit eviii effective january scheringploughs year end december saving advantage plan amend restate attached effective january supplemental executive retirement plan amend attach restate january retirement benefit equalization plan amend attach restate january executive incentive plan amend restate incorporate reference exhibit schering october ploughs year end december defer compensation plan amend restate incorporate reference exhibit schering october plough year end december amend restate define contribution trust incorporate reference exhibit aii schering plough year end december amend restate serp rabbi trust agreement incorporate reference exhibit schering plough year end december cholesterol governance agreement date incorporate reference exhibit schering scheringplough merck inc ploughs date october party signatory thereto amendment cholesterol governance incorporate reference exhibit schering agreement date december plough file october scheringplough merck inc party signatory thereto master agreement date december incorporate reference exhibit schering scheringplough merck inc ploughs file october party signatory thereto table content xhibi number description location letter agreement date april relate consent incorporate reference exhibit schering decree plough period end march distribution agreement scheringplough incorporate reference exhibit schering centocor inc date april plough amend year end december file amendment agreement distribution agreement incorporate reference exhibit schering centocor inc development llc plough file december scheringplough ireland company share purchase agreement akzo nobel incorporate reference exhibit schere scheringplough international scheringplough plough file october corporation computation ratio earning fix charge attach standard global business practice cover incorporate reference exhibit schere employee include senior financial officer plough file september subsidiary registrant attach consent independent register public accounting attach firm independent auditor consent attach power attorney attach sarbanesoxley act section certification attach chairman board chief executive officer sarbanesoxley act section certification attach executive vice president chief financial officer sarbanesoxley act section certification attach chairman board chief executive officer sarbanesoxley act section certification attach executive vice president chief financial officer compensatory plan contract arrangement certain portion exhibit omit pursuant request confidential treatment nonpublic information file separately security exchange commission pursuant rule securities exchange act amend copy exhibit furnish request table content signature pursuant requirement section securities exchange act registrant duly cause report sign behalf undersigned thereunto duly authorize scheringplough corporation registrant steven koehler steven koehler vice president controller duly authorize officer chief accounting officer date february pursuant requirements securities exchange act report sign follow person behalf registrant capacity date indicate fred hassan chairman board chief executive officer fred hassan robert bertolini executive vice president chief financial officer robert bertolini steven koehler vice president controller steven koehler director hans becherer director thomas colligan director robert kidder director eugene mcgrath director carl mundy director antonio perez director patricia russo director jack stahl director craig thompson table content director kathryn turner director robert van oordt director arthur weinbach steven koehler steven koehler attorneyinfact date february table content merckscheringplough cholesterol partnership combine statement net sale contractual expense year ende dec ber dollar million net sale cost sale sell general administrative research development income operation accompany note integral combine financial statement table content merckscheringplough cholesterol partnership combine balance sheet mber dollar million asset cash cash equivalent account receivable net inventory prepaid expense asset total asset liability partner capital rebate payable payable merck net payable scheringplough net accrue expense liability total liability commitment contingent liability note partner capital total liability partner capital accompany note integral combine financial statement table content merckscheringplough cholesterol partnership combine statement cash flow yea ende dece ber dollar million operating activity income operation adjustment reconcile income operation net cash provide operating activity account receivable net inventory prepaid expense asset rebate payable payable merck scheringplough net accrue expense liability noncash charge net cash provide operating activity financing activity contribution partner distribution partner net cash financing activity net increasedecrease cash cash equivalent cash cash equivalent begin period cash cash equivalent end period accompany note integral combine financial statement table content merckscheringplough cholesterol partnership combine statement partner capital deficit chere plough merck total dollar millions balance january contribution partner income operation distribution partner balance december contribution partner income operation distribution partner balance december contribution partner income operation distribution partner balance december accompanying note integral combine financial statement table content merckscheringplough cholesterol partnership note combine financial statement description business basis presentation description business merck inc merck scheringplough corporation scheringplough collectively partner enter agreement agreement jointly develop market united states scheringplough investigational cholesterol absorption inhibitor cai ezetimibe market today united states zetia ezetrol countrie cholesterol collaboration fixedcombination tablet contain active ingredient montelukast sodium loratadine respiratory collaboration montelukast sodium leukotriene receptor antagonist sell merck singulair loratadine antihistamine sell scheringplough claritin indicate relief symptom allergic rhinitis respiratory collaboration terminate accordance applicable agreement follow receipt notapprovable letter food drug administration fda fixedcombination tablet cholesterol collaboration formally refer merckscheringplough cholesterol partnership partnership december cholesterol collaboration agreement expand include country world japan cholesterol collaboration agreement provide ezetimibe develop market follow form ezetimibe daily cai nonstatin cholesterol reduce medicine coadministere statin drug ezetimibe simvastatin merck exist zocor statin cholesterol modifying medicine combine tablet market today united states vytorin inegy country vytorin zetia approve fda july october respectively product market vytorin zetia trademark locally refer cholesterol product cholesterol collaboration agreement partner establish jointlyowne limited purpose legal entity base canada united states carry contractual activity partnership country additional jointlyowne limited purpose legal entity base singapore establish right intellectual property fund oversee research development manufacturing activity cholesterol collaboration market latin america subsidiary merck scheringplough perform marketing activity cholesterol product contract partnership legal entity subsidiary operation collectively refer combine company latin america partnership sell directly schere plough merck latin american subsidiary scheringplough merck compete cholesterol market consequently sell promotion distribution activitie cholesterol product latin america include combine company partnership substantially reliant infrastructure merck scheringplough limited number employee legal entity partnership activity perform employee merck scheringplough service agreement partnership profit share partner differ arrangement country world generally define net sale minus agree manufacturing cost expense incur partner invoice partnership direct promotion expense incur partner invoice partnership expense limited specialty sale force united states incur partner invoice partnership certain amount sale force physician detail cholesterol product united states puerto rico canada italy administration expense base percentage cholesterol product net sale invoice partner cost expense incur table content merckscheringplough cholesterol partnership note combine financial statement continue partner contemplate cholesterol collaboration agreement enter subsequently agree partner agree research development expense incur partner invoice partnership share equally partner adjust special allocation nature milestone partner partnership future result operation financial position cash flow differ materially historical result present risk uncertaintie relate partnership business partnership future operating result cash flow dependent cholesterol product event adversely affect market product significant impact partnership result operation cash flow event include loss patent protection increase cost associate manufacturing increase competition introduction new effective treatment exclusion government reimbursement program discontinuation removal market product safety reason result future clinical outcome study note basis presentation accompany combine balance sheet combine statement net sale contractual expense cash flow partner capital deficit include cholesterol respiratory collaboration activity combine company respiratory collaboration activity primarily pertain clinical development work prelaunch marketing activity spending respiratoryrelate activity cease follow termination collaboration material income operation year present net sale include net sale cholesterol product sell combined company expense include amount merck scheringplough contractually agree directly invoice partnership share contractual profit sharing arrangement partner describe accompany combine financial statement prepare purpose comply certain rule regulation securities exchange commission reflect activity partnership base contractual agreement partner combine financial statement include expense agree partner share include calculation profit contractual agreement partnership intend complete presentation cost expense incur standalone pharmaceutical company discovery development manufacture distribution marketing pharmaceutical product cholesterol collaboration agreement certain activity charge partnership partner base contractually agree allocation partnerincurre expense describe opinion management allocation expense describe basis reasonably reflect actual level support provide expense expense partner reflect separate consolidated financial statement describe profit share arrangement cholesterol collaboration agreement provide certain partner incur cost expense invoice partnership partner profit sharing calculation follow paragraph list typical category cost expense generally incur discovery development manufacture distribution marketing cholesterol product provide description cost expense treat accompany combine statement net sale contractual expense determine profit contractual agreement manufacturing cost expense contractually agree manufacture plant cost expense incur partner relate manufacture cholesterol product include cost sale accompany combine statement net sale contractual expense include table content merckscheringplough cholesterol partnership note combine financial statement continue direct production cost certain production variance expense plant service administration warehouse distribution material management technical service quality control asset utilization manufacturing cost expense incur partner agreed include determination profit contractual agreement invoice partnership exclude accompany combine financial statement cost expense include limited yield gain loss excess jointly agree yield rate excessidle capacity manufacture plant asset direct promotion expense direct promotion represent direct identifiable outofpocket expense incur partner behalf partnership include limit contractually agree expense relate market research detail aids agency fee directtoconsumer advertising meeting symposia trade program launch meeting special sale force incentive program product sample contractually agree expense include sell general administrative accompany combine statement net sale contractual expense promotion expense incur partner agree include determination profit contractual agreement exclude accompany combine financial statement sell expense united states canada puerto rico market outside united states primarily italy general sale force partner provide majority physician detail activity agree cost include sell general administrative accompany combine statement net sale contractual expense addition agree cost limited specialty sale force united states market call opinion leader field cholesterol medicine include sell general administrative selling expense incur partner agreed include determination profit contractual agreement exclude accompany combine financial statement expense include total cost general sale force partner detail cholesterol product country united states canada puerto rico italy administrative expense administrative support primarily provide partner contractually agree expense support determine base percentage net sale cholesterol product amount include sell general administrative accompany combine statement net sale contractual expense select contractually agree direct cost employee partner support service outofpocket expense incur partner behalf partnership include sell general administrative expense incur partner agreed include determination profit contractual agreement exclude accompany combine financial statement expense include limited certain manage care service partner subsidiary management international market indirect expense corporate overhead interest research development expense activity perform partner agree cost expense invoice partnership agree expense generally represent allocation partner estimate time equivalent devote preclinical postmarkete clinical development regulatory activity include grant thirdparty expense contractually agree allocate cost include research development accompany combine statement net sale contractual expense cost incur partner jointly agree exclude accompany combine financial statement table content merckscheringplough cholesterol partnership note combine financial statement continue summary significant accounting policy principles combination accompany combine balance sheet combine statement net sale contractual expense cash flow partner capital deficit include cholesterol respiratory collaboration activity combine company interpartnership balance profit eliminate use estimate combine financial statement prepare base contractual agreement partner describe include certain amount base management good estimate judgment estimate determine item provision sale discount return government manage care rebate uncertainty inherent estimate actual result differ estimate foreign currency translation net asset partnership foreign operation translate dollar current exchange rate dollar effect arise translate net asset operation include partner capital significant cash cash equivalent cash cash equivalent primarily consist highly liquid money market instrument original maturity month partnership change certain cash management practice increase cash hold partnership partnership cash primarily invest highly liquid money market instrument fund trade obligation come month distribution partner interest income earn cash cash equivalent report reduction sell general administrative accompany combine statement net sale contractual expense amount million million million respectively inventory substantially inventory value low cost market intangible asset intangible asset consist license trademark trade name own partnership intangible asset record partner historical cost date contribution nominal value revenue recognition rebate return allowance revenue sale cholesterol product recognize title risk loss pass customer recognition revenue require reasonable assurance collection sale proceed completion performance obligation net sale vytorininegy zetiaezetrol year end december follow millions vytorininegy zetiaezetrol total united states sale discount issue customer direct discount pointofsale indirectly intermediary wholesale purchaser know chargeback indirectly form rebate additionally sale generally limited right return certain condition sale record net provision table content merckscheringplough cholesterol partnership note combine financial statement continue sale discount return reliable estimate time sale reserve chargeback discount return allowance reflect direct reduction account receivable amount million million december respectively accrual rebate reflect rebate payable show separately combine balance sheet income taxis generally taxable income loss partnership allocate partner include partner income tax return state jurisdiction partnership subject income tax include combine financial statement share partner income taxis significant combine financial statement provision federal foreign state income taxis december partnership million defer tax asset comprise solely net operating loss carryforward nol generate branch legal entity partnership nol expire carry valuation allowance january partnership adopt financial accounting standard board interpretation accounting uncertainty income taxis fin adoption fin impact partnership financial statement concentration credit risk segment information partnership concentration credit risk consist primarily account receivable partnership normally require collateral security support credit sale bad debt year end december minimal december customer represent account receivable net customer account net sale show table cent sales mckesson drug company cardinal health inc amerisourcebergen corp partnership derive approximately combine net sale united states respectively termination respiratory collaboration respiratory collaboration terminate accordance applicable agreement follow receipt approvable letter fda propose montelukastloratadine combination tablet result termination scheringplough receive million incremental allocation partnership profit allocation certain profit termination impact cholesterol collaboration inventory inventory december consist million finish good raw material work process total partnership enter longterm agreement partner supply active pharmaceutical ingredient api formulation packaging cholesterol product table content merckscheringplough cholesterol partnership note combine financial statement continue agree cost connection supply agreement partnership enter capacity agreement partnership commit specify annual minimum supply api formulate tablet pay penalty capacity agreement effect period seven year follow year production partner expire begin partnership payment obligation capacity agreement december relate party transaction partnership receive substantially good service include pharmaceutical product manufacturing service sale force service administrative service service partner partnership net payable merck scheringplough service million million respectively december million million respectively december sell general administrative expense include contractually define cost physician detail provide scheringplough merck million million respectively million million respectively million million respectively expense necessarily reflective actual cost partner sale effort country amount contractually define include amount million million million respectively relate contractually define cost physician detail italy amount invoice pay partnership partner component profit sharing calculation cost sale sell general administrative expense include contractually define cost distribution administrative service provide merck scheringplough million million million respectively amount necessarily reflective actual cost distribution administrative service partnership sell cholesterol product directly partner principally merck scheringplough affiliates latin america latin america partner compete cholesterol market merck scheringplough purchase cholesterol product partnership sell directly party sale partner include net sale invoice price accompany combine statement net sale contractual expense total million million million respectively legal matter partnership party claim legal proceeding nature consider normal business include product liability intellectual property partnership record liability connection matter probable liability incur reasonably estimate legal cost associate litigation investigation activity expense incur partnership maintain insurance coverage deductible selfinsurance management believe cost beneficial partnership selfinsure risk relate product liability accrue estimate product liability claim incur report february scheringplough receive notice glenmark pharmaceuticals inc usa glenmark generic pharmaceutical company indicate file abbreviate new drug application anda generic form zetia challenge patent list zetia march scheringplough partnership file patent infringement suit glenmark parent company lawsuit automatically stay fda approval glenmark anda early october adverse court decision scheringplough partnership intend vigorously defend patent believe valid infringement generic company attempt table content merckscheringplough cholesterol partnership note combine financial statement continue market product prior expiration date patent litigation assurance outcome adverse result significantly shorten period exclusivity january partner announce result effect combination ezetimibe highdose simvastatin simvastatin atherosclerotic process patient heterozygous familial hypercholesterolemia enhance clinical trial image trial patient heterozygous familial hypercholesterolemia rare genetic condition cause high level ldl bad cholesterol greatly increase risk premature coronary artery disease despite fact ezetimibesimvastatin vytorin significantly lower ldl bad cholesterol simvastatin significant difference treatment ezetimibesimvastatin simvastatin prespecifie primary end point change thickness carotid artery wall year measure ultrasound significant difference treatment ezetimibesimvastatin simvastatin prespecifie key secondary end point percent patient manifest regression average carotid artery intimamedia thickness imt proportion patient develop new carotid artery plaque change average maximum imt change average imt plus average common femoral artery imt enhance compare simvastatin ezetimibesimvastatin significantly lower ldl bad cholesterol triglyceride creactive protein crp ezetimibesimvastatin indicate reduction crp enhance study overall safety profile ezetimibesimvastatin generally consistent product label enhance study design power evaluate cardiovascular clinical event improve reduction highrisk subject present acute coronary syndrome improveit trial underway design provide cardiovascular outcome data ezetimibesimvastatin patient acute coronary syndrome incremental benefit ezetimibesimvastatin cardiovascular morbidity mortality demonstrate simvastatin establish march result enhance report annual scientific session american college cardiology january fda announce complete review final clinical study report enhance fda state result enhance change position elevate ldl cholesterol risk factor cardiovascular disease lower ldl cholesterol reduce risk cardiovascular disease fda state base current available datum patient stop take vytorin cholesterol lower medication talk doctor question vytorin zetia enhance trial july efficacy safety result simvastatin ezetimibe aortic stenosis sea study announced sea design evaluate intensive lipid lower vytorin reduce need aortic valve replacement risk cardiovascular morbidity mortality versus placebo patient asymptomatic mild moderate aortic stenosis indication statin therapy vytorin fail meet primary end point reduction major cardiovascular event significant difference key secondary end point aortic valve event reduction group patient take vytorin compare placebo key secondary end point ischemic cardiovascular event vytorin indicate treatment aortic stenosis incremental benefit vytorin cardiovascular morbidity mortality demonstrate simvastatin establish study patient group take vytorin high incidence cancer group take placebo nonsignificant increase death cancer patient group take vytorin versus take placebo cancer cancer death distribute major organ system partner partnership believe cancer finding sea likely anomaly take light available datum support association vytorin august fda announce investigate result sea trial announcement fda cite interim datum large ongoing cardiovascular trial vytorin study heart renal protection sharp improveit clinical trial increase risk cancer combination table content merckscheringplough cholesterol partnership note combine financial statement continue simvastatin plus ezetimibe sharp trial expect complete improveit trial schedule completion fda determined time finding sea trial plus interim datum ongoing trial prompt patient stop take vytorin cholesterol lower drug partner partnership commit work regulatory agency evaluate available data interpretation datum believe change clinical use vytorin warrant previously disclose december merck scheringplough receive letter address companies house committee energy commerce subcommittee oversight investigation rank minority member senate finance committee collectively seek combination witness interview document information variety issue relate enhance clinical trial sale promotion vytorin sale stock corporate officer merck scheringplough addition august partner receive additional letter include date february seek certain information document relate seas clinical trial previously disclose partner partnership receive subpoenas new york new jersey state attorney general office letter connecticut attorney general seek similar information document addition partner partnership receive civil investigative demand cid multistate group state attorney general jointly investigate violation state consumer protection law occur market vytorin finally september merck scheringplough receive letter civil division department justice doj inform doj investigate company conduct relate promotion vytorin cause false claim submit federal health care program partner partnership cooperate investigation respond inquiry addition partner partnership aware serve approximately civil class action lawsuit allege common law state consumer fraud claim connection partnership sale promotion vytorin zetia certain lawsuit allege personal injury andor seek medical monitoring action file transfer federal court coordinate multidistrict litigation district court district court new jersey district judge dennis cavanaugh party presently engage motion practice brief feasible predict outcome investigation lawsuit arise enhance sea clinical trial unfavorable outcome significant adverse effect partnership financial position result operation cash flow table content independent auditor report partner merckscheringplough cholesterol partnership audit accompany combine balance sheet merckscheringplough cholesterol partnership partnership december describe note relate combined statement net sale contractual expense partner capital deficit cash flow describe note year period end december financial statement responsibility management partnership merck inc scheringplough corporation responsibility express opinion financial statement base audit conduct audits accordance generally accept auditing standard establish auditing standard board united states accordance auditing standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement partnership require engage perform audit internal control financial reporting audits include consideration internal control financial reporting basis design audit procedure appropriate circumstance purpose express opinion effectiveness partnership internal control financial reporting accordingly express opinion audit include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion accompany statement prepare purpose comply certain rule regulation securities exchange commission describe note intend complete presentation financial position result operation cash flow activity standalone pharmaceutical company involve discovery development manufacture distribution marketing pharmaceutical product opinion financial statement refer present fairly material respect combine financial position merckscheringplough cholesterol partnership describe note december combine result net sale contractual expense combine cash flow describe note year period end december conformity accounting principle generally accept united states america deloitte touche llp parsippany new jersey february table content scheringplough corporation subsidiary schedule valuation qualifying account year end december valuation qualifying account deduct asset apply allowance account receivable serve eserve eserve doubtful cash claim account discount total dollar million balance beginning year addition charge cost expense deduction reserve effect foreign exchange balance end year balance beginning year obs reserve acquire november addition charge cost expense deduction reserve effect foreign exchange balance end year balance beginning year addition charge cost expense deduction reserve effect foreign exchange balance end year